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Abstract 
 
Title: Application of the Linear Quadratic Model to Targeted Radionuclide 
Therapy 
 
The principal aim of this work was to test the hypothesis that the Linear-
Quadratic (LQ) model of cell survival, developed for external beam 
radiotherapy (EBRT), could be extended to targeted radionuclide therapy 
(TRT) in order to predict dose-response relationships. The secondary aim was 
to establish the relevance of particular radiobiological phenomena to TRT and 
relate these results to any deviations from the response predicted by the LQ 
Model. 
Methods: Cancer cell lines were treated with either EBRT or an in-vitro model 
of TRT. Dosimetry for the TRT was calculated using radiation transport 
simulations with the Monte Carlo PENELOPE code. Clonogenic as well as 
functional biological assays were used to assess cell response. 
Results: Accurate dosimetry for in-vitro exposures of cell cultures to 
radioactivity was established. LQ parameters of cell survival were established 
for cancer cell lines reported to be prone to apoptosis, low dose 
hypersensitivity (LDH) or the bystander effect.  
For apoptotic cells and cells exhibiting a bystander effect in response to EBRT, 
LQ parameters were found to be predictive of cell response to TRT. Apoptosis 
was not found to be a mode of cell death more specific to TRT than to EBRT. 
Bystander effects could not be demonstrated in cells exposed to TRT. 
Exposure to low doses of radiation may even protect against the bystander 
effect.  
The LQ model was not predictive of cell response in cells previously shown to 
exhibit LDH. This led to a development of the LQ model based upon a 
threshold dose-rate for maximum repair. However, the current explanation of 
LDH may not explain the inverse dose-rate response. 
Conclusion: The LQ model of cell survival to radiation has been shown to be 
largely predictive of response to low dose-rate irradiation. However, in cells 
displaying LDH, further adaptation of the model was required.   
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1 Introduction 
The aim of this work was to analyse the biological response of tumour cell lines 
that have been irradiated by prolonged low-dose rate beta irradiation as used 
in targeted radionuclide therapy (TRT). 
There are a number of alternative methods of delivering a localised toxic dose 
of radiation in the treatment of cancer patients. Firstly, a focussed dose of 
radiation can be delivered using overlapping beams of radiation delivered from 
external sources such as linear accelerators. This is the most common form of 
radiation delivery in oncology and will be referred to as External Beam 
Radiotherapy Treatment (EBRT). Secondly, brachytherapy techniques may be 
used, whereby a localised radiation dose is delivered by inserting (either 
temporarily or permanently) a sealed radioactive source in situ within the 
patient.  The third option is to deliver multi-site doses of radiation using TRT. 
Although it is also possible to directly inject a radiopharmaceutical into a single 
target, the principle of TRT is that a radiopharmaceutical is incorporated or 
bound onto a biological target or targets, and delivers a localised prolonged 
dose of ionising radiation to each target. It is hoped that, due to specific binding 
of the radiopharmaceutical to the target only, other parts of the body are not 
targeted in the same way and that therefore unwanted radiation dose to those 
areas is avoided.  One of the major advantages of this technique is that by 
relying on a biological process for localising the radiation source, it may be 
possible to effectively treat metastatic disease. This is not the case with EBRT 
or brachytherapy treatments.  
Hence the aim of the therapy is that clinically significant doses of radiation can 
be delivered to multiple sites of metastatic disease, without the limiting side-
effects that can occur with other systemic treatments such as chemotherapy.  
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1.1 TRT in the Treatment of Cancer 
1.1.1 Radioiodine and Differentiated Thyroid Cancer 
The use of radionuclide therapy as it is understood today, whereby an 
unsealed source is incorporated into a radiopharmaceutical that “seeks out” its 
biological target, dates back to the 1940s when the first treatments using 
iodine-131(131I) were carried out on patients with thyrotoxicosis, a benign 
thyroid disease [1].  
131I remains widely used today in the treatment of thyrotoxicosis and has also 
become established as a routine tool used in the clinical management of 
differentiated thyroid carcinoma (DTC). Iodide is taken up in both papillary and 
follicular carcinoma cells via the sodium / iodide symporter (NIS). Following 
diagnosis and subsequent thyroidectomy, 131I is used to target and destroy any 
remaining thyroid cells, including any sites of metastases.  
Overall long term survival rates for thyroid cancer are close to 90% ,[2, 3]. In 
the case of follicular thyroid cancer, 10 year survival is 85% whilst for papillary 
thyroid cancer it is 93% [4]. Although this relatively high survival rate is also 
due to improved diagnostic and surgical techniques, radionuclide therapy for 
differentiated thyroid carcinoma using 131I is widely perceived as a highly 
successful form of cancer therapy [5, 6].  
1.1.2 TRT in Treatment of Neuroendocrine Tumours 
More recently, radionuclide therapy has established a role in the treatment of 
neuroendocrine tumours (NETs). Neuroendocrine cells are specialised 
hormone producing nerve cells that occur within the hormone secreting set of 
organs known as the endocrine system. Again 131I was the first radionuclide to 
be used in this field, in the context of radiolabelled metaiodobenzylguanidine 
(MIBG). In this case, the 131I is incorporated into the MIBG molecule which is 
an analogue of noradrenalin and is actively taken up by NETs via the 
Noradrenalin Transporter (NAT). 
131I-MIBG has been used therapeutically since the 1980s in the treatment of 
neuroblastoma [7,8], malignant phaeochromocytomas [9] as well as other 
NETs. However in contrast with the success of radioiodine for treatment of 
metastatic DTC, the use of 131I-MIBG has generally resulted in a palliative 
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effect only and is not seen as a treatment that will result in a complete 
response [10, 11, 12].  
More recently, NETs have also been imaged and treated using radiolabelled 
peptides that bind to specific somatostatin receptor targets which are 
overexpressed on the surface of the NET cancer cells. As an administered 
drug, native somatostatin has a relatively short half-life in blood. Consequently, 
a number of  more stable somatostatin analogues have been developed and 
radiolabelled [13].  
Initial therapeutic treatments were carried out using 111In-DTPA Octreotide, on 
the assumption that the radiopharmaceutical was internalised within the cell 
and that Auger electrons (see section 1.2), emitted as part of the 111In 
radioactive decay were responsible for any therapeutic effect. Further 
developments in radiopharmacy resulted in the labelling of the octreotide 
analogue with yttrium-90 (90Y), a pure beta emitter. The use of 90Y is a logical 
development, since the lack of a gamma emission should in theory allow a 
higher radiation dose to be delivered to the tumour burden whilst reducing the 
radiation dose to the rest of the patient. More recent advances have included 
the development of a new analogue octreotate, labelled with the beta emitting 
lutetium-177 (177Lu) [14]. 
A review of peptide therapy using somatostatin analogues by Kwekkeboom et 
al showed the following range of responses to such radionuclide therapies [15]. 
As with 131I-MIBG, complete responses are a rare outcome. 
 
Table 1.1 Patient Response to Neuroendocrine TRT 
RADIOPHARMACEUTICAL PATIENTS %CR %PR %MR %SD %PD 
111
IN-DTPA OCTREOTIDE 26 0 0 19 42 38 
111
IN-DTPA OCTREOTIDE 26 0 2 NA 81 12 
90
Y-DOTA OCTREOTIDE 21 0 6 NA 52 19 
90
Y-DOTA OCTREOTIDE 74 4 15 NA 65 11 
90
Y-DOTA OCTREOTIDE
 
33 6 27 NA 57 9 
90
Y-DOTA OCTREOTIDE
 
54 0 7 13 61 19 
177
LU-DOTA OCTREOTATE 76 1 29 12 39 18 
 
CR: Complete Remission PR: Partial Remission MR: Minor Response 
SD: Stable Disease  PD: Progressive Disease 
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1.1.3 Radio-immunotherapy  
Radiolabelled somatostatin analogues are an example of using peptide 
receptors as a biological target. An alternative targeting mechanism is the use 
of radio-labelled antibodies that are associated with specific antigens produced 
by a particular cancer type.  
As with peptide therapy, the first use of this technique was in cancer imaging 
rather than therapeutic applications [16]. However, during the past thirty years 
the technique has been developed culminating in the approval of two 
commercially available radioimmunotherapy (RIT) agents for the treatment of 
Non-Hodgkin’s Lymphoma – 90Y-ibritumomab (Zevalin; IDEC Pharmaceuticals 
Corporation) and 131I-tositumomab (Bexxar; Corixa and GlaxoSmithKline 
Corporations). 
In a randomised control trial, patients were treated with either a combination of 
Zevalin and the unlabelled antibody, or the cold antibody alone. An overall 
response rate of ~80% was demonstrated in patients receiving Zevalin 
compared to an overall response rate of 56% for the group treated with cold 
antibody only [17]. Complete responses were observed in 30% of Zevalin 
treated patients compared to 15% of non-Zevalin treated patients. Similar 
results have been observed with Bexxar [18]. 
1.1.4 Palliative Treatment of Bone Metastases 
Another example of TRT that has become a routine clinical tool is the palliative 
treatment of multiple sites of bone metastases, primarily in breast, myeloma 
and prostate cancer patients [19]. A variety of different radiopharmaceuticals 
exist, such as 89SrCl2, 
186Re-HEDP, 188Re-HEDP and 153Sm-EDTMP which all 
target bone metastases.  Despite covering a wide spectrum of radiation 
emissions and half-lives, no definitive advantage of one over another has been 
established. 
1.1.5 Novel Developments in TRT 
The examples of TRT described have become routinely applied tools in the 
treatment of various cancers. Although the lack of complete responses, 
particularly in the case of NETs, can be viewed as disappointing, TRT options 
are often considered as the most effective treatments available in a particular 
setting. Therefore research into new potential targets continues, whilst a 
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number of methods for enhancing the use of current radiopharmaceuticals are 
also under evaluation. 
Advances in gene therapies mean that it is now possible to transfect a cell in 
order that it expresses receptors or targets that would not normally occur.  This 
approach has also been used in combination with radionuclide therapy by 
transfecting malignant cells, with a transgene encoding the noradrenalin 
transporter (NAT) such that non-NET cells will take up 131I-MIBG. This 
approach has been applied to both gliomas [20, 21] and adenocarcinoma of 
the prostate [22]. However, it is worth noting that to date, this approach has 
only been used on an in-vitro basis.  
Consideration has also been given to carrying out TRT in combination with 
other therapeutic modalities such as external beam radiotherapy [23, 24] or 
chemotherapy [25]. The hypothesis of such studies is that the therapeutic 
effect of combining treatment is greater than the sum of the benefits when such 
treatments are carried out individually. Again, it should be noted that clinical 
validation of such schemes has not yet been established. 
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1.2 Treatment Planning and Dosimetry in TRT 
1.2.1 Absorbed Dose 
Ionising radiation is a form of energy which, when delivered to a target volume, 
results in the deposition of some or all of that energy within that target. The 
fundamental measure of the energy deposited is the absorbed dose, defined 
as the energy per unit mass. 
m
ED     
 Equation 1.1 
 
E is the energy measured in Joules, m is the mass in kg and D is measured in 
Grays (Gy). Alternatively absorbed dose may be expressed in eV/g. 
1.2.2 Radionuclide Emissions 
In the context of radiation therapy, including both EBRT and brachytherapy, a 
number of different types of radiation emissions have been used or are under 
investigation.  
 
Alpha Particles: 
24
2
4
2→

  HeYX
A
Z
A
Z      
Equation 1.2 
 
 
An alpha particle is a helium nucleus consisting of two neutrons and two 
protons ejected from the unstable parent nucleus. The kinetic energy of such 
particles may range from 4 to 9MeV. Typical ranges in tissue are 10-6 m. 
 
Beta Particles: 
1-
1→ eYX
A
Z
A
Z      
Equation 1.3 
 
Beta particles are negatively charged electrons and are emitted with a 
spectrum of kinetic energy, the maximum energy of which depends on the 
radionuclide. As these electrons interact with the material through which they 
travel, they cause ionisations, leading in turn to further electrons. The majority 
of radionuclides used for TRT are beta emitters. 
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Gamma Rays: 
Gamma ray photons are non-particulate emissions with much longer ranges in 
human tissue and are consequently not desired in TRT, although high energy 
photon beams (typically 6MeV) are used in external beam radiotherapy. To 
date, the bulk of radiobiology research has concerned the use of such photon 
beams.  
 
Electron Capture, Internal Conversion and Auger Electrons: 
Energy is not always dissipated by ejecting particles from the atomic nucleus. 
In a process known as electron capture, proton rich nuclei may absorb an 
electron from those orbiting around the nucleus, resulting in conversion of a 
proton to a neutron and emission of a neutrino.   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.1 Schematic of characteristic X-ray / auger electron production 
 
 
Internal conversion is a process whereby the energy of an excited nucleus is 
transferred to an orbital electron which is subsequently ejected from the atom. 
Thus the electrons may have a similar energy to beta emissions but are 
distinguished by their origin from the orbital rather than the nucleus. 
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Both electron capture and internal conversion lead to a vacancy in the electron 
orbit. Higher valence orbital electrons will move to fill the vacancy, thus moving 
from a higher energetic state to a lower state. The difference in energy is 
generally released in the form of an X-ray, but a proportion of this energy may 
be transferred to other orbiting electrons which are subsequently emitted from 
the atom (see figure 1.1). Such electrons are called Auger electrons and have 
a much lower energy spectrum than beta emissions. These energies are 
usually of the order of eV and consequently have much shorter ranges in 
tissue than beta particles. They have been used to some extent in TRT, e.g. in 
the case of 111In-somatostatin analogs, tumour toxicity is due to Auger 
emissions.  
 
1.2.3 Linear Energy Transfer and Cross-Fire 
The Linear Energy Transfer (LET) is a measure of the energy transferred to a 
medium per unit path length by ionising radiation particles. Alpha particles and 
Auger electrons are classified as high-LET particles, whilst beta particles are 
classified as low-LET particles. 
Despite the low-LET of their emissions, the principal radionuclides used at 
present for TRT are all beta emitters. Although the energy imparted across the 
whole path length of the particle is relatively low, the energy is not distributed 
evenly along the path. As the beta particle loses energy, the probability of 
interaction with the tissue medium in which it travels increases, and hence the 
pathway of the particle will end in a cluster of ionisation events. In addition, 
there is also the possibility that excited orbital electrons will be released with 
sufficient energy to cause further ionisation events themselves. 
This deposition of energy may be simulated using Monte Carlo radiation 
transport codes, as illustrated in figure 1.2. Simulated interactions for a beam 
of 978keV electrons representative of Low LET beta particles, and a beam of 
500eV electrons representing High LET Auger electrons are shown. 
Although the ranges of the Auger electrons are much lower, the high density 
distribution of the high LET radiation means that, for a given dose of radiation 
the energy deposition is more concentrated within the cell and that therefore 
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high LET radiation is considered to have a higher relative biological efficiency 
(RBE) than that of low LET radiation.  
 
 
Figure 1.2 PENELOPE simulation of electron shower for A) 978keV monoenergetic electrons, 
illustrative of 
90
Y emissions, LET = 0.26keV/m and B) 500eV monoenergetic electrons, 
illustrating Auger electrons emitted by 
125
I, LET = 25keV/m 
 
 
In fact, when a cluster of cells is considered, it is likely that any response to 
ionising radiation from a particular cell will be due to a radiation particle 
originating from a radionuclide attached to another cell a particular distance 
100nm 
1cm 
A) 
B) 
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away, rather than any radionuclide attached to the affected cell. This effect is 
termed cross-fire and is considered to be one of the advantages of using beta 
irradiation. 
 
1.2.4 Treatment Planning 
As previously stated, the aim of any radiotherapy is to deliver a high dose of 
radiation to a particular target or set of targets, whilst delivering minimal doses 
to the rest of the body.  
When a patient receives external beam radiotherapy, it is standard clinical 
practice to prescribe a particular dose of radiation to the tumour volume, and to 
subsequently plan the way in which this treatment can be delivered. This relies 
on a well established understanding of the behaviour of radiation beams in 
human tissue and a sophisticated methodology for calculating the dose 
delivered throughout the patient.  
In the case of TRT, the standard clinical practice that has evolved, is to 
prescribe all patients a fixed amount of radioactivity at regular intervals 
(typically every 6 months). Routinely little, if any, consideration is given to 
calculating the absorbed dose to either the tumour volumes or to critical organs. 
This may be explained by the technically challenging nature of such dosimetric 
calculations, coupled with the high success rate of these empirical protocols 
using radioiodine in DTC.  
However, in order to maximise the potential of other radiopharmaceuticals, 
there has been a renewed interest in dosimetry and treatment planning in TRT. 
Firstly, establishing dosimetry of critical organs, such as bone marrow in the 
case of 131I-MIBG, or the kidneys in the case of 90Y-Octreotate, has been used 
to establish the maximum level of radioactivity that can be safely administered 
on an individual patient basis [26, 27]. Furthermore there is also a desire to 
calculate the radiation dose to the tumour, and attempt to relate this to a likely 
outcome and prognosis [28] . 
For EBRT, the absorbed dose is determined by considering the position and 
intensity of the various radiation beams directed through a patient. In the case 
of TRT, the absorbed dose is a combination of the amount of radioactivity 
initially administered to the patient as well as the biodistribution and biokinetics 
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of the radiopharmaceutical within that patient. Hence, the challenge of TRT 
dosimetry is firstly to quantify the distribution of radioactivity, as a function of 
both space and time, and secondly to use this data to calculate the absorbed 
dose to a particular target.  A number of different methods exist to meet these 
aims and are discussed below. 
  
1.2.5 Medical Internal Radiation Dose (MIRD) Internal Dosimetry  
Initial assessments of internal radiation dosimetry from radiopharmaceuticals 
date back to the 1960s when assessments were made of exposures from 
radiopharmaceuticals designed for diagnostic use. Recall from equation 1.1 
that the total absorbed dose to a target is the sum of the ionising radiation 
energy absorbed within that target, divided by its mass.  Since the absorbed 
energy originates from the radionuclide emissions, it is first necessary to 
calculate the total number of decays over the treatment time considered. This 
is referred to as the cumulative activity and is defined as 

T
AdtA 0
~
 
 
Equation 1.4 
T is the treatment time and A is the radioactivity at time t.  
 
Under the Medical Internal Radiation Dose (MIRD) system [29, 30], a 
“reference man” was constructed from a series of phantoms that could be used 
to represent the different organs of the body filled with varying concentrations 
of a particular radionuclide. The principle of MIRD is to simulate radioactivity in 
one organ at a time and to calculate the absorbed dose to all other organs in 
the body, as well as to the source organ itself. Since absorbed dose is defined 
as the energy absorbed per unit mass, the dose from any organ acting as a 
source of radioactivity to a given target (which may or may not be the source) 
is given as  
m
A
D STST





~
 
Equation 1.5 
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where Δ is the average energy emitted by the radionuclide, φ is the fraction of 
energy absorbed in terms of a specific target and organ pair and m is the mass 
of the target organ.  
It is common to group these parameters into a single factor. Thus, in the 
equation below, the S-factor accounts for the average energy of the various 
radionuclide emissions in the source organ, and the fraction of that energy 
absorbed by a particular target organ. 
~
ASD   
Equation 1.6 
 
By repeating this exercise for all organs, it is possible to build a look-up table 
linking the absorbed dose to all organs within the body, with the cumulative 
activity measured for each organ. 
Although widely adopted for dosimetry of diagnostic radiopharmaceuticals, the 
method suffers from several disadvantages when applied to a patient 
undergoing TRT.  
The physical distribution of an individual patient is not precisely represented by 
an average “reference man”, both in terms of the size of the various organs 
and the distance between them. Both of these factors affect the accuracy of 
the derived S-factors.  
In addition, the model also suffers from the assumption that organs have 
homogenous uptake of the radionuclide. In the case of a cancer patient with a 
metastatic disease burden this is often not the case and indeed it is not 
possible to define a tumour within the context of “reference man”.  
 
1.2.6 Voxel Based Internal Dosimetry with Point Kernels 
When using MIRD, time-activity curves for various organs would typically be 
measured using a sequence of 2D planar images. However, modern methods 
of imaging, using either Single Photon Emission Computed Tomography 
(SPECT) or Positron Emission Tomography (PET), mean that accurately 
quantifying the distribution of a radionuclide in 3D is increasingly possible.  
These developments in imaging technology have led to more accurate and 
appropriate techniques for treatment planning of TRT patients. The space-time 
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distribution of the radiopharmaceutical is measured in four dimensions using 
sequential PET or SPECT images, using either a positron or gamma emitting 
version of the radiopharmaceutical. The physical distribution of tumour and 
organs within the patient is established through the use of a CT scan. By 
registering the sequential images, it is then possible to calculate the cumulative 
activity on a voxel by voxel basis, rather than considering the whole organ. 
Thus these scans provide a basis for calculating the dose distribution (see 
figure 1.3). Although sets of S-factors relating the cumulative activity in one 
voxel to the absorbed dose in all voxels are available, an alternative technique 
known as dose point kernel convolution may also be used. A dose point kernel 
is a function describing the dose distribution around a unit activity, located in a 
single voxel. By convolving this function (defined as a function of the spatial 
parameter ρ) with the distribution of cumulative activity (defined as a function of 
the spatial parameter r) a patient specific absorbed dose distribution is derived. 
 
       ddrArD  


~
 
Equation 1.7 Convolution of cumulative activity with dose point kernel 
 
The disadvantage of this technique is the fact the dose point kernel is normally 
simulated in water. Hence, the convolution technique will not take account of 
significant tissue inhomogeneities such as bone or lung tissue.  
  
 
Figure 1.3 Derivation of Voxel Based Dose Distribution 
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1.2.7 Monte Carlo Radiation Transport Simulation 
The deposition of energy by ionising radiation is a result of a series of energy 
losses by the radiation particles emitted. The laws of physics, which govern 
these interactions are precisely known, and probability distributions of 
particular outcomes may be calculated for given input data: i.e. given an initial 
energy, direction and a description of the material through which it moves, it is 
possible to a) simulate the potential path of a single particle and all the 
secondary particles to which it gives rise, and b) track the deposition of energy 
within that material. For a single particle, this is a stochastic process for which 
repeating the simulation is unlikely to provide the same answer. If however, 
this simulation is repeated for millions of particles then it is possible to build up 
an accurate and precise measure of the macroscopic pattern of interactions 
and dosimetry that would occur in a simulated situation.  
Such Monte Carlo simulations find widespread use in dosimetry and are used 
to provide data for MIRD S-factors, as well as generating the point dose 
kernels described above. Furthermore it is possible to overcome the 
disadvantage of the point dose kernel technique regarding inhomogeneities, by 
including a CT scan of the patient in the Monte Carlo simulation. The 
distribution of the radiopharmaceutical is provided by either a SPECT or PET 
scan.  
In addition the use of radiation transport codes can be extended to the 
microscopic scale, in order to assess dosimetry at the cellular level. In the 
various models used to consider the dosimetry of TRT, an assumption is often 
made of a uniform distribution of radiopharmaceutical, whether that is on the 
macroscopic scale in the case of the MIRD system for organ dosimetry, or at 
the scale of voxel based dosimetry still of the order of several millimetres.  
However, it is known that at the cellular level this will not be the case, even 
with tumours that appear uniform on imaging [31]. It is expected that this will 
have a significant effect on the cellular dose distribution and subsequent 
response of the cell population, particularly in the case of low range emissions 
such as Alpha particles or Auger electrons [32, 33]. 
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1.2.8 Dose-Response Relationships in Clinical TRT 
The emergence of these ever more sophisticated dosimetry techniques has led 
to a number of evaluations of the correlation between dose and response. 
Early assessments of dose-response in patients treated for differentiated 
thyroid carcinoma, suggested an absorbed dose of 300Gy was necessary for 
successful ablation [34, 35]. More recently, Flux et al showed that successful 
ablation could occur at much lower doses [36]. Although they showed a 
statistically significant difference in the absorbed dose to the thyroid remnant 
between successful and unsuccessful treatments, there remained a substantial 
overlap between the failed ablations (7-49Gy) and complete eradication of the 
thyroid (12-470Gy). Thus absorbed dose alone was shown not to predict 
treatment outcome.  
Analysis of patient outcome in the context of treating Non-Hodgkin’s 
Lymphoma with 131I-tositumomab (Bexxar) showed no correlation with tumour 
dose [37]. However, a significant correlation was found by Dewaraja et al (in 
the same clinical setting) when they calculated Equivalent Uniform Dose (see 
1.3.5) instead of absorbed dose only [38]. 
It is not just important to establish dose-response relationships in tumours. It is 
often more important to be able to predict the tolerance in critical organs at risk 
from the administered radioactivity. For example, in radiopeptide therapy, it is 
usually the kidneys which are the dose-limiting organ. A review of 18 patients 
by Barone et al showed no correlation between kidney absorbed dose and 
renal toxicity. When Biologically Effective Doses (see 1.3.5) were calculated to 
take account of differences in dose-rate a much clearer relationship was 
observed (r=0.93) [39].  
The outcome of these results overall, has been the recognition that absorbed 
dose alone may not predict response to treatment, and that in future phase III 
trials designed to appraise the potential benefits of dosimetry and treatment 
planning, radiobiological modelling appropriate to TRT should be utilised [40, 
41].  
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1.3 Radiobiology for TRT 
Despite the advances made in internal dosimetry, the actual dose necessary to 
elicit a favourable response in a patient is not well known [42].  For example, 
investigations into palliative treatment of bone metastases have shown no 
correlation between dose and response [43-45]. 
The vast majority of radiobiology research has been carried out at dose-rates 
typical of external beam radiotherapy, given over minutes as opposed to the 
days that can be taken to deliver a TRT dose. In order to further improve the 
design of trials of new therapeutic approaches to TRT, it is essential to have an 
accurate description of the energy deposition both within tumour and normal 
cells. However, that information must be complemented by an understanding 
of the radiobiological responses relating to such methods of radiation dose 
delivery.  
1.3.1 Interactions of radiation with cells and DNA 
The interaction of radiation with cells can be considered as either direct or 
indirect. In the first situation the radiation directly causes the ionisation of a 
particular atom or group of atoms that make up part of a biological target, e.g. 
DNA. The ionisation may initiate a chemical change that may in turn lead to a 
biological change.  
In the case of indirect interaction, the radiation will ionise other atoms or 
molecules within a cell (water being the most likely example) leading to the 
creation of highly reactive free radical species. Although free radicals are short 
lived, they may react with the biological target, thus leading to a biological 
change.  
Although ionisation events will occur throughout the cell, the most sensitive 
target when irradiating cells has long been established as the DNA within the 
cell nucleus. For example, short range high LET alpha particles emitted by 
polonium-210 (210Po) were shown to be lethal at a dose of 1Gy when localised 
to the nucleus. When localised to the cell membrane, a dose of 250Gy was 
required to reduce the rate of cell growth [46]. The damage that can occur to 
DNA ranges from single and double strand breaks in the backbone of DNA, 
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damage to the base subunits of DNA, to cross-links between the DNA strands 
as well as DNA and nuclear proteins. 
Single strand breaks are breaks in the DNA chain and are thought to occur as 
a result of free radical attacks on the chemical bonds along the DNA chain. A 
double strand break describes a similar situation, although the break has 
occurred on both opposing chains. These latter are considered to be more 
lethal and harder to repair since a single strand break may be repaired with 
reference to the corresponding complementary base. It is single and double 
strand breaks that are traditionally thought to have the greatest correlation with 
cell death. 
 
1.3.2 Response of Cells to Radiation  
Free radicals within the cell do not occur solely as a result of irradiation and are 
in fact an everyday occurrence. It is estimated that between 10,000 and 
150,000 oxidative lesions are produced each day in each cell, as a result of 
reactive oxygen species (ROS) produced as by-products of common cellular 
processes [47]. Consequently a number of DNA repair processes normally 
exist and these will also be activated in response to ionising radiation. 
The response of cells in dealing with damaged DNA may be divided into three 
components: Recognition of damage, a period of damage assessment, 
followed by either repair or cell death [48]. 
Initial DNA damage results in the increased activity of proteins such as ataxia 
telangiectasia mutated (ATM) and DNA dependent protein kinase (DNA-PK) 
As damage is “detected” via these mechanisms a number of proteins may be 
subsequently activated in order to promote repair of the cell DNA. It is common 
to observe cell cycle arrest following irradiation and a number of different 
checkpoints have been described [49]. 
Under normal circumstances, cells may move through the cell cycle as 
illustrated in figure 1.4. During mitosis (M phase) a cell will divide to produce 
two daughter cells. The remaining three phases are collectively known as 
interphase. The S phase is the phase during which DNA transcription activities 
occur. G1 and G2 are so called gap phases which occur between S phase and 
M phase as shown.  
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Figure 1.4 Cell Cycle 
 
In order to progress from phase to another, a particular set of proteins known 
as cyclins must form complexes with enzymes called cyclin-dependent kinases 
(CDKs). The diagram below illustrates the pathways initiated by ATM that can 
lead to cell cycle arrest in response to DNA damage. 
 
 
Figure 1.5 Cell Cycle Checkpoints 
 
As can be seen, ATM activates the human checkpoint kinase 2 (Chk2) which in 
turn phosphorylates Cdc25A and Cdc25C. These proteins are necessary in 
order to activate the CDK1 kinase associated with the G2/M transition. Thus 
their phosphorylation renders them inactive and therefore blocks the cell cycle.  
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ATM also activates the p-53 protein, which will in turn activate a further protein 
p-21. These will bind to and therefore inactivate the cylin-E-CDK2 complex that 
governs the passage from G1 to S phase.  
The subsequent delay in cell cycle progression allows a period of DNA repair 
to proceed, either by homologous recombination whereby the corresponding 
section of the sister chromatid is used as a template for repair, or by non-
homologous end-joining in which repair is carried out independently.  
Following cell cycle checkpoints, any unrepaired cells may either proceed with 
cell division (mitosis) or undergo programmed cell death (apoptosis). If a cell 
undergoes mitosis without having made necessary repairs and still contains 
DNA breaks or chromosome aberrations, then that cell will normally undergo a 
passive form of cell death termed necrosis. Necrotic cells are characterised by 
loss of cell membrane integrity, cell swelling, and random fragmentation of 
DNA. Apoptotic cells on the other hand, are observed to have more ordered 
DNA fragmentation and break down into small apoptotic bodies. Necrotic cell 
death is thought to be more likely following exposure to higher radiation doses, 
whereas apoptosis has been associated with lower levels of radiation dose [50] 
[51]. 
1.3.3 Clonogenic Cell Survival 
A further alternative to both necrosis and apoptosis is accelerated senescence, 
whereby a cell does not die but does lose its ability to divide. It is important to 
note that the relevant end-point, when considering TRT of cancer cells, is not 
necessarily cell death but whether the irradiated cells retain the ability to 
reproduce. As such, it is common to characterise response to different levels of 
irradiation through the use of a clonogenic assay, in which individual cells are 
seeded throughout a culture medium and incubated. After a certain period of 
time, colonies of cells are counted and compared to the number of colonies 
formed by a non-irradiated negative control sample.   
 
1.3.4 The Linear Quadratic Model  
In describing the clonogenic response of cells to radiation, a number of 
different models have been proposed. Of these, the Linear Quadratic model 
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has become the most well established as a radiobiological model in external 
beam therapy, principally due to its ease of use and its successful fit to the 
experimental data [47, 52]. 
The surviving fraction (SF) of cells after a single instantaneous exposure to 
ionising radiation, resulting in an absorbed dose D, is predicted by the 
expression:- 
 2DDeSF    
Equation 1.8 
 
where  and  are tissue specific parameters. The  term has been linked 
conceptually to the creation of double strand breaks by a single ionisation 
event whilst the  term has been linked to the creation of a double strand break 
caused by adjacent single strand breaks, arising from two unrelated ionisation 
events. As the dose is increased, the probability of the second type of event 
increases and hence the quadratic term in the equation becomes more 
important. A typical cell survival curve is shown in the figure below (=0.2, 
=0.02).  
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Figure 1.6  Clonogenic Survival Curve 
 
Such curves are plotted on a log-linear scale and tend to be characterised by a 
linear shoulder before the curve bends away.  
In the context of EBRT, one of the main reasons that the LQ model has 
become particularly popular is the way in which it predicts the outcome of 
fractionating the delivery of radiotherapy. Fractionation involves the splitting of 
the delivery of the total dose into a number of smaller doses, delivered at 
regular intervals (normally 24 hours). The LQ model in its most simple form 
assumes that sub-lethal damage is repaired between fractions such that when 
the next fraction is delivered the damage is independent of any previous 
radiation events. For example if a dose of 20Gy was delivered in 4 fractions of 
5Gy each, the survival curve for the cell line in the figure above would appear 
as shown in figure 1.7. Effectively the portion of the surviving fraction curve up 
to 5Gy is replicated 4 times, resulting in a less effective treatment. The LQ 
model predicts this effect according to the equation  
 
    22 expexp ndndddSF n    
Equation 1.9 
 
where n is the number of fractions and d is the dose per fraction.  
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Figure 1.7 The Effect of Dose Fractionation 
 
The reason for applying this apparently less effective treatment is seen by 
considering the effect of radiation on normal tissues. These tissues tend to be 
characterised by a broader shoulder, such that the effect of fractionating the 
dose delivery is to spare normal tissues from unwanted side effects. 
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Figure 1.8 Dose Sparing Effect. Survival curves are shown for A) Acute delivery of radiation to 
malignant tissue (=0.5, =0.05) and normal tissue (=0.1, =0.33). B) Fractionated (n=20) 
delivery of radiation to the same hypothetical tissues. 
 
This model for fractionating dose delivery has also been extrapolated by Dale 
to the modelling of dose-rate effects [104]. An increasingly lower dose-rate and 
protracted time for dose delivery can be considered equivalent to delivering the 
radiation dose in a number of fractions with an increasingly large value of n 
and decreasing value of d.  
1.3.5 Radiobiological Dosimetry 
As the previous section makes clear, the measure of total absorbed dose alone 
does not provide an indication of outcome without being placed into context. 
For example, dose-rate or fractionation scheme, tumour radiosensitivity, as 
A) 
B) 
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well as dose distribution within a tumour, will all play a part in determining the 
response to radiation. 
Therefore a number of further parameters have been defined which seek to aid 
comparison of alternative treatment plans. The first of these is the Biologically 
Effective Dose (BED) which is defined by the following equation.  
 

SF
BED
ln  
Equation 1.10 
 
The BED which has units of Gy is a conceptual term. It represents the dose 
that would be required if treatment was delivered such that there was complete 
repair of damage associated with the  parameter, to match the effect of the 
treatment under consideration. This allows comparison of alternative treatment 
regimes including TRT.  
The LQ model provides a means of calculating the surviving fraction of a 
collection of cells, assumed to have the same radiosensitivity. It can be seen 
that the higher the number of cells present, the higher the probability that some 
will survive. The Tumour Control Probability (TCP) is a concept that accounts 
for this factor and is defined as follows [24, 53]. Since complete tumour 
eradication is a rare outcome in TRT, the relevance of this parameter to this 
treatment modality is perhaps debatable.  
 
 
 )exp(exp
exp
0
0
BEDN
SFNTCP


 
Equation 1.11 
 
The Equivalent Uniform Dose (EUD) is a concept in considering the 
effectiveness of treatments in which absorbed dose is not evenly distributed 
over a target volume. It is defined as the BED which, if distributed uniformly 
over the same volume, would result in the same Surviving Fraction [54]. 
Although, it was originally defined as a concept to be applied to Intensity 
Modulated Radiotherapy (IMRT), it has nonetheless been applied by others to 
treatments with TRT [38]. 
  

SFEUD ln1  
Equation 1.12 
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1.3.6 Dose-rate, Apoptosis and TRT 
There is a sizeable opinion expressed in the literature that models developed 
for EBRT may not translate directly to TRT where doses are delivered at dose-
rates several orders of magnitude lower than is the case in EBRT. 
Apoptosis, also known as “programmed cell death” was originally described by 
Kerr et al in 1972 [55].  Apoptotic response is characterised morphologically by 
an ordered set of changes such as cell shrinkage, the cleaving of DNA into 
regular subdivisions and the breakdown of the cell into smaller membrane 
bound apoptotic bodies. 
A wide variety of pathways have been described that lead to a cell undergoing 
apoptosis. Essentially these can be subdivided into “intrinsic” pathways, where 
the process is initially triggered within the cell, or extrinsic pathways triggered 
by receptors in the cell membrane.  
As has been described, apoptosis is a mechanism for cell death thought to be 
more predominant at lower doses in EBRT. Since TRT is a low dose-rate 
treatment, the hypothesis that apoptosis is the predominant pathway for cell 
death in this modality has been widely discussed and reported in the literature 
[27, 56, 57]. One group who measured apoptosis in gamma and beta-irradiated 
HL60 leukaemia cells, using both FACS analysis and Western Blot techniques, 
found that comparable levels of apoptosis were observed when either 
technique was used [58]. However, their results also suggested a higher rate of 
apoptosis when the dose-rate used to deliver the beta-irradiated dose was 
lowered. Another group also confirmed the induction of apoptosis in a HeLa 
Hep2 cell line using a low dose-rate gamma source as a surrogate for TRT 
treatment [59]. 
 
1.3.7 Hypersensitivity and Increased Radioresistance 
A further phenomenon observed during in-vitro experiments on EBRT, is that 
of low dose hypersensitivity (LDH). When certain cell lines are exposed to 
acute radiation doses of the order of ~10cGy, clonogenic assays demonstrate 
a surviving fraction lower than that which would be predicted using the LQ 
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model. As the dose is increased, the surviving fraction then increases (i.e. 
radioresistance appears to increase) before then falling away as would be 
anticipated by the LQ model [60]. This hypersensitivity has been explained by 
low doses failing to trigger repair mechanisms that would normally repair DNA 
damage, and in particular a failure of cell cycle checkpoints preventing 
damaged cells passing into mitosis [61]. This has led to further investigations 
into the effect of dose-rate upon cell survival in the context of TRT. When cell 
lines that had been demonstrated to show LDH behaviour in response to acute 
doses of gamma radiation were exposed to protracted dose deliveries of the 
order of 10-100 cGy/hour, an inverse dose-rate effect was observed whereby 
lower surviving fractions resulted from lower dose-rate treatments [62]. In 
contrast, cell lines that did not demonstrate LDH failed to show this effect.  
 
1.3.8 Alternative Targets / Bystander Effect  
Although the cell nucleus of a cell is seen as the principal target in irradiation, 
evidence has accrued within the last twenty years for other mechanisms 
leading to cell death.  
A number of responses have been classified as non-targeted responses [63] 
whereby biological effects are not thought to be specifically related to DNA 
damage. One of the most interesting of these has been the bystander effect. 
The bystander effect is a phenomenon whereby cells that have not been 
directly irradiated, may undergo the same response as neighbouring cells that 
have been irradiated. Clinical evidence for the bystander effect dates back as 
far as the 1950s [64] when plasma transferred from irradiated patients resulted 
in chromosome breakages in human lymphocytes. Further in-vitro evidence 
was demonstrated by irradiating cells in culture, spinning down the suspension 
and transferring the media to unirradiated cell culture, which then 
demonstrated a response. More recently, groups have used radiation micro-
beams to target individual cells with alpha particles and then observed 
responses in neighbouring cells. Although interest in the bystander effect has 
been predominant amongst the radiation protection community, its role in the 
context of TRT has also been the subject of investigation. Boyd et al, 
experimenting with human glioma and bladder carcinoma cells, found that 
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when using gamma irradiation the cell killing effect of medium from irradiated 
cells reached a plateau after ~2Gy radiation dose. On the other hand, the cell 
killing effect of media from 131I-MIBG  irradiated cells continued to increase as 
the dose administered was increased. In the case of alpha irradiation, the 
bystander effect was observed to reach a peak at ~5Gy before the effect then 
diminished as the dose was increased [65].  
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1.4 Aims and Objectives 
The principal aim of this work was to test the hypothesis that the Linear 
Quadratic model developed and routinely applied to external beam 
radiotherapy can be extended to targeted radionuclide therapy.  
In order to assess dose-response relationships, it was first necessary to 
establish and validate an accurate dosimetry technique that would provide the 
link between the amount of radioactivity to which cell cultures were exposed 
and the resulting absorbed dose. To this end, chapter 3 is a description of the 
use of the PENELOPE (PENetration and Energy Loss of Positrons and 
Electrons) Monte Carlo algorithm to meet these requirements.  
The subsequent chapters make use of this dosimetry to investigate the dose 
response of both haematological and solid tumour cell cultures. In each 
instance, cell lines were first treated with different doses of single fraction 
EBRT in order to characterise the  and  parameters describing cell survival 
with respect to the Linear Quadratic model. The same cell lines were then 
exposed to low dose-rate irradiation using 90Y. Measured cell survival was 
compared to the survival predicted using Dale’s version of the LQ model 
developed specifically for a monoexponentially decaying rate of irradiation 
[104]. 
In chapter 4 this approach is taken with two leukaemia cells lines, HL60 and 
MOLT-4. In addition, the hypothesis that cancer cells are more likely to enter 
apoptosis when treated with low dose-rate irradiation rather than EBRT was 
investigated.  
In chapter 5, the application of the LQ model to cells displaying Low Dose 
Hypersensitivity was investigated. The first aim of this chapter was to explore 
modifications to the LQ model that could predict any observed increase in 
sensitivity to lower dose-rate treatment. Furthermore, an investigation was also 
made of the hypothesis that the biological explanation applied to Low Dose 
Hypersensitivity was the underlying mechanism to any observed increase in 
the sensitivity of cells to low dose-rate irradiation. 
Chapter 6 concentrates on the response of cells which are able to effect a 
bystander response when treated with EBRT. Media transfer experiments were 
used to investigate whether such responses could be elicited when cells were 
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treated with low dose-rate irradiation, as well as whether the LQ model was an 
appropriate tool in predicting cell survival. 
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2 Materials and Methods 
 
2.1 Materials 
 
2.1.1 Reagents 
 
Reagent Supplier 
  
0.25%( (w/v) Trypsin – 0.53mM EDTA solution Cambrex 
111
InCl Covidien 
1M EDTA  BLT Pharmacy 
3%  Methycellulose in Iscove’s Modified Dulbeccos 
Medium 
R&D Systems 
90
YCl Perkin Elmer 
Ammonium Acetate Prepared In House 
Ammonium Acetate with 50mM EDTA Prepared In House 
ATM antibody Abcam 
ATM-p1981 antibody Cell Signalling 
Bovine Serum Albumin Sigma-Aldrich 
Bromophenol blue Sigma-Aldrich 
BT-474 Barts Cancer Institute 
Caspase-Glo® 3/7 Assay Promega 
CellTiter-Glo® Cell Viability Assay Promega 
Chk2-p antibody Cell Signalling Technology 
Crystal Violet Sigma-Aldrich 
DOTA Macrocyclics 
ECL Reagent GE Healthcare 
FCS Invitrogen 
Herceptin BLT Chemotherapy Unit 
HL60 Clare Hall, Cancer Research UK 
Methanol BDH Laboratory 
MOLT-4 Clare Hall, Cancer Research UK 
Mouse Secondary Dako 
PBS Barts Cancer Institute 
PC-3 Barts Cancer Institute 
Poly-HEMA Sigma-Aldrich 
Protease Inhibitor Calbiochem 
Protein A sepharose beads GE Healthcare 
Protein assay Biorad 
Protein L sepharose beads GE Healthcare 
Protogel National Diagnostics 
Rabbit Secondary Dako 
RPMI-1640 Barts Cancer Institute 
SDS Tris-Glycine Fischer 
Tween 20 Sigma-Aldrich 
TEMED GE Healthcare 
Trypan Blue Sigma-Aldrich 
YAML568 Therapeutic Antibody Centre (Oxford) 
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2.1.2 Equipment 
 
Equipment Supplier 
1282 CS Universal Gamma Counter LKB Wallac 
Allegra 21R centrifuge Beckman Coulter 
Chromatography Column Biorad 
Cylcone plus storage phosphor system Perkin Elmer 
Developer G138i curix 60 processor AGFA 
Incubator Binder 
Microscope Wilovert 
Plate Reader Beckman Coulter 
Radioisotope Calibrator Capintec 
IBL 637 Blood Irradiator CIS Biointernational 
  
  
 
2.1.3 Software  
 
Software Supplier 
Graphpad Prism5 (Statistics)  Graphpad Inc 
ImageJ National Institute of Health 
PENELOPE Monte Carlo Nuclear Energy Agency 
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2.2 Cell Culture 
2.2.1 Cell Lines 
A number of different cell lines were used during this work. All cell lines were 
cultured in a 37°C incubator containing 5% CO2. Non-adherent human HL60 
acute promyelocytic leukaemia cells were grown in RPMI-1640 medium, 
supplemented with 10% Fetal Calf Serum (FCS). Human lymphoblastic MOLT-
4 cells were also grown in identical conditions. Cells were split and media was 
replaced three times per week. 
PC-3 human prostate adenocarcinoma cells were grown in RPMI-1640 (10% 
FCS) at 37°C in 5% CO2. Cells were split using trypsin-EDTA 2-3 times per 
week. BT-474 breast cancer cells were grown in RPMI-1640 supplemented 
with 20% FCS at 37°C in 5% CO2. Cells were split once per week, using 
trypsin-EDTA, although media was changed every 2-3 days. All cells were 
regularly tested for mycoplasma and were all also type tested to confirm their 
identity. 
 
2.2.2 BT-474 Spheroid Formation 
BT-474 cells were grown as spheroids, using a method based on that 
described by Ivascu and Kubbies [66]. The monolayer of cells was detached 
using trypsin-EDTA and resuspended in fresh media.  Cells were pipetted to 
ensure clumps of cells were separated into single cells. The absolute cell 
concentration was determined using a haemocytometer and the Trypan Blue 
assay. Cell numbers ranging from 1,000 to 20,000 per well were added to 
round bottomed 96 well plates, depending on the size of spheroid required. 
The 96 well plates had been precoated with 80l 0.5% poly-hydoxyethyl-
methacrylate (Poly-HEMA) dissolved in 95% ethanol, and air dried at 37°C for 
48 hours. The purpose of the Poly-HEMA was to prevent cells adhering to the 
well plates. Spheroid formation was encouraged by initially centrifuging the 
plates at 400 rpm for 8 minutes before leaving the plates for 24 hours at 37°C 
in 5% CO2. 
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Spheroid diameters were measured by pipetting the formed spheroid onto a 
haemocytometer. Spheroids of 1,000 cells were found to have a diameter of 
375m. 
 
2.3 External Beam Irradiation 
Single Fraction EBRT was delivered using an IBL 637 blood irradiator (CIS 
Biointernational) containing a caesium-137 (137Cs) source. The irradiator was 
made available by Cancer Research UK, who also maintained it with a regular 
program of Quality Control.  
Samples were placed in a shielded chamber. When the machine was activated 
the chamber became exposed to the 137Cs source with an activity of the order 
of TBq resulting in a dose-rate of approximately 4Gy/min. Absorbed doses to 
samples were controlled by presetting an appropriate exposure time.  
All cell cultures exposed to EBRT in this way were aliquoted in 10ml samples 
into 25cm2 flasks and placed at the centre of the irradiation chamber in a 
position of known dose-rate.  
In addition to making dosimetric calculations based upon the known dose-rate 
in the chamber, absorbed doses were verified using an instant read-out 
dosimeter. 
 
2.4  Targeted Radionuclide Therapy Irradiation 
Three alternative radiopharmaceuticals were used to provide low dose-rate 
irradiation to cell cultures. In the first instance, simulation of low dose-rate TRT 
was provided by 90Y- Ethylenediaminetetraacetic acid (EDTA). This provided a 
means of creating a uniformly radioactive media due to the lack of specific 
uptake by cells. This provided a mode of irradiation which could be modelled 
by Monte Carlo methods as described more fully in chapter 3. This 
radiopharmaceutical was used to investigate dose-response relationships in 
apoptotic cell lines (chapter 4), hypersensitive cell lines (chapter 5) and in BT-
474 cells (chapter 6). 
In the case of the BT-474 cell line used in chapter 6, a means of targeting the 
cells specifically was also required. The BT-474 cells are known to express the 
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HER-2 receptor [67] which is the target of the commercial immunotherapy 
Trastuzumab (Herceptin). Therefore Herceptin was labelled with 90Y.  
For the purposes of bystander effect experiments with BT-474, a 
radiopharmaceutical was sought that could subsequently be extracted from cell 
culture media. Therefore 90Y was also labelled to the YAML568 antibody, thus 
providing a means of non-specific irradiation that could subsequently be 
separated from the media (unlike 90Y-EDTA).  
 
2.4.1 90Y-EDTA Labelling 
90Y was provided in the chemical form of 90YCl3 (Perkin Elmer) in 102l 0.05M 
HCl . 90Y-EDTA was produced as follows. 100l 0.1M EDTA was added to 
900l 0.1M ammonium acetate. An equal volume of the buffered EDTA was 
then added to an equal volume of 90YCl, depending on the amount of 
radioactivity required.  
2.4.2 90Y-DOTA-Herceptin Labelling and Binding Assay 
Expired clinical grade Herceptin, with a concentration of 25mg/ml, was 
obtained from the Chemotherapy unit of Barts and the London NHS Trust. The 
Herceptin was tested for aggregation or contamination using High Pressure 
Liquid Chromatography (HPLC). This showed a single peak at a molecular 
weight of 150kDa indicating no aggregation or contamination of the antibody.  
In order to radiolabel Herceptin with 90Y, tetraazacyclododecanetetraacetic 
acid (DOTA) was used as a chelator, to link the Herceptin antibody to the 
yttrium metal ions. DOTA molecules were conjugated with the Herceptin as 
outlined by Cooper et al [68].  The conjugated antibody was aliquoted into 
60x12ml aliquots, each containing 50g of Herceptin, and stored at -20°C. 
Conjugated DOTA-Herceptin aliquots were labelled with radioactivity as 
follows:- 1l of 0.1M ammonium acetate was added to the volume of 90YCl3 
required (generally 10l, equivalent to 20MBq)  in an Eppendorf tube. The 
purpose of the ammonium acetate was to maintain a pH of 5.5 during the 
labelling reaction. 2 x 10l of the DOTA-Herceptin was then added, such that 
the total volume within the Eppendorf was no more than 30l. If the combined 
volume of the above was less than 30l, the difference was made up using 
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sterile water for injection. The reaction mixture was incubated at 37°C for 4 
hours. 
Radiolabelling was verified using Thin Layer Chromatography (TLC) on a 
routine basis. Briefly, 0.1M ammonium acetate with 50mM EDTA solvent was 
added to a 50ml Falcon tube to a depth of 0.5-1cm. A 1l sample of the 
radiolabelled Herceptin was dropped onto a strip of Whatman paper, such that 
when the strip was placed vertically in the Falcon tube, the site of the sample 
was just above the level of the solvent. After the solvent front had risen along 
the strip to its far end, the strip was removed and left to dry. The dried strip was 
placed on a piece of radiosensitive film (within a cassette) for approximately 1 
minute. The film was then imaged on a phosphor imager and the resulting 
images analysed to identify the proportion of activity that had not moved along 
the silica strip with the solvent. This activity was assumed to be the 
radiolabelled antibody. 
Labelling was initially tested using 111InCl3 instead of 
90YCl3. In the case of 
111In, 
labelling efficiencies (i.e. the proportion of radioactivity bound to Herceptin) of 
88% were measured after 1 hour incubation (using TLC), rising to 93% after 4 
hours. This compared to an HPLC measurement of labelling efficiency of 91% 
after 4 hours. When the procedure was repeated using 90Y, labelling 
efficiencies of >95% were achieved at 4 hours, as measured using TLC. 
Before carrying out dose-response experiments, a binding assay was carried 
out to ensure specific binding between 90Y-DOTA-Herceptin and the BT-474 
cell line. 
For the binding assay, cells were prepared by harvesting half a large flask of 
cells and centrifuging at 1000rpm. The cells were then washed with 0.5% 
albumin in Phosphate Buffer Solution (PBS) and resuspended in a volume of 
4ml. A 1ml sample of this cell culture was added to an Eppendorf tube and 
then serially diluted into further tubes, such that 5 x 0.5ml aliquots of cell 
culture were produced with relative concentrations of 1: 2: 4: 8: 16. A further 
0.5ml sample of the undiluted cell culture was added to a tube labelled as 
“non-specific binding”. A 50l sample of 2mg/ml Herceptin was added to this 
sample in order to saturate all the HER2 binding sites. Meanwhile, the 
radiolabelled DOTA-Herceptin was diluted to a concentration of 50ng/ml. 250l 
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aliquots of the antibody were added to all cell preparations as well as to an 
empty Eppendorf tube. The purpose of this tube was to provide a measure of 
the maximum potential radioactivity that could bind to the cells. All of the above 
preparations were carried out in duplicate.  
The Eppendorf tubes were placed in 50ml Falcon tubes and left on rollers for 2 
hours to allow any binding of the radiolabelled antibody to the cells. After 2 
hours cell samples were spun down and the pellets washed with 0.5% albumin 
PBS. The pellets were then assayed for radioactivity in a gamma counter 
alongside the tubes representative of the total activity added to each cell 
sample. 
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Figure 2.1 Binding Assay results for A)In-111 DOTA-Herceptin and B) Y-90 DOTA Herceptin 
with BT-474 HER2 expressing breast cancer cell line 
 
A) 
B) 
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As figure 2.1 shows, there was clearly specific binding of both 111In-DOTA-
Hercpetin and 90Y- DOTA-Herceptin to the BT-474 cell line. In the case of 90Y- 
DOTA-Herceptin absolute measurements of the radioactivity of the cell pellets 
were made by using a Gamma Counter to compare the counts from the 
samples with those from a standard derived from the original 90YCl3 of known 
concentration. These were combined with measurements of cell number made 
using a haemocytometer in order to produce figure 2.2. The results suggested 
that a monolayer of BT-474 cells in a 6 well plate, would not take up the 
amounts of radioactivity required for the dose-response experiments. 
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Figure 2.2 Binding of Y90-DOTA-Herceptin to BT-474 cells in terms of absolute levels of 
radioactivity and cell number 
 
Therefore attempts were made to increase the specific activity of the 90Y- 
DOTA-Herceptin by decreasing the ratio of DOTA-Herceptin (by volume) 
relative to the 90YCl3 during the labelling reaction. The original ratio used was 
2:1 as described above. The effect of reducing this ratio was to rapidly 
decrease the labelling efficiency achieved (see Table 2.1). Therefore, it was 
decided to maintain the ratio of 2:1 for all dose-response experiments. 
In any case, a wide variation in cell binding was noted during the course of 
several dose-response experiments. The reason for this is potentially 
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explained by variations in specific activity / impurity content for different 
production runs of the 90YCl3. 
 
 
Table 2.1 Labelling Efficiency of 
90
Y-DOTA-Herceptin 
Ratio of DOTA-Herceptin to 
90
YCl3 
(by volume) 
Labelling Efficiency after 1 hr 
2:1 91.0% 
1:2.5 82.8% 
1:5 64.9% 
1:25 0% 
 
2.4.3 90Y-DTPA-YAML568 Labelling and Binding Assay 
For the purpose of bystander effect experiments, a radiolabelled antibody that 
would not bind to BT-474 cells, and could subsequently be extracted from the 
cell culture media in which irradiated cells were incubated, was required.  
YAML568 is a rat IG2A monoclonal antibody which specifically binds to the 
CD45 antigen. This antigen was not thought to be expressed by the BT-474 
cells (YAML568 was developed to target malignant cells in patients with acute 
myeloid leukemia prior to undergoing stem cell transplantation [58].)  
A stock of already conjugated DTPA-YAML568 (4mg/ml) was already available 
within the laboratory at the Barts Cancer Institute. The labelling was carried out 
in a similar way to the labelling of 90Y-DOTA-Herceptin. 1l of 0.1M ammonium 
acetate was added to 20l of 90YCl3, (40MBq) in an Eppendorf tube. Two test 
labellings were carried out – in the first case 10l DTPA-YAML568 was added 
to the radioactivity and in the second case 40l DTPA-YAML568 was added.  
Radiolabelling was assessed as described in chapter 2.4.2 using TLC. After 4 
hours, labelling efficiency was found to be 90% and 95% respectively for the 
labellings described above. 
A binding assay was carried out (as described in chapter 2.4.2) in order to 
confirm that CD45 was not expressed by BT-474 cells, and that the 
radiolabelled antibody would not bind to the cells. This was indeed confirmed 
to be the case. (See figure 2.3.) 
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Figure 2.3 Binding Assay results for Y-90 DTPA-YAML568 with BT-474 breast cancer cell line 
 
 
 
2.4.4 Media Transfer Experiments 
In order to explore a bystander response in cell lines exposed to external beam 
irradiation, the following protocol was used. Donor cell cultures were exposed 
to 137Cs irradiation as previously described. Following irradiation, cells were 
further incubated for a period of 24 hours. After this time, suspension cell 
cultures were spun at 1000rpm for five minutes. The resulting supernatant was 
then removed and added to a recipient cell culture of the same cell type, such 
that 50% of the total cell media in the recipient cell culture was derived from 
the irradiated cell culture.  
In the case of adherent cell cultures, the entire cell culture volume was 
aspirated from the recipient cell cultures and replaced with the cell culture 
taken from the donor cells. The donor cells were subsequently discarded. 
Following media transfer, all recipient cell cultures were incubated for a further 
24 hours prior to clonogenic assay. 
For treatments using TRT, (namely 90Y-DOTA-Herceptin or 90Y-DTPA-
YAML568) it was necessary to extract the radioactivity from the cell culture 
media. A method based on that used for purifying antibodies was used, namely 
Protein A or Protein L affinity chromatography. Protein A and Protein L are 
immunoglobulin binding proteins which specifically bind to particular antibody 
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isotypes. Protein A was required to extract 90Y-DOTA-Herceptin whilst Protein 
L was required to extract 90Y-DTPA-YAML568. 
Single use chromatography columns were loaded with 0.4ml Protein A/L beads 
in 70% ethanol (GE Healthcare). This column was then washed 5 times with 
10% FCS RPMI media in order to remove the ethanol, before loading the 
column with the 2.5ml of cell culture volume used to irradiate plated BT-474 
cells. This media was collected separately from the media used for washing 
the column, and repeatedly passed through the column in order to remove the 
radiolabelled antibody. All of the above was carried out in a laminar flow 
cabinet, so as to maintain sterility. Relative measurements of the radioactivity 
of the Protein A/L column and the filtered cell culture media were made using a 
radionuclide calibrator.  
Complete extraction of the radioactivity was not possible in either case. For 
both Protein A / 90Y-DOTA-Herceptin and Protein L / 90Y-DTPA-YAML568, the 
amount of radioactivity removed from the media saturated at 85%. (See figure 
2.4.) 
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Figure 2.4 Extraction of Y90-DTPA-YAML568 from RPMI media using Protein L Column 
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2.5 Internal Dosimetry Calculations 
For all investigations of response to low dose-rate irradiation, it was necessary 
to establish a link between the radioactivity added to the cell cultures and the 
resulting absorbed dose to the cells. Unlike the case of the external beam 
treatments with 137Cs, it was not possible to establish in-vitro measuring 
techniques that could verify the absorbed dose at the cellular level. Therefore 
the dose-response investigations presented in chapters 4-6 make use of 
calculations of absorbed dose which took the following form. 
 
 TeAS
ASD




10
~
 
Equation 2.1 
 
Ã is the cumulative activity. i.e. the total number of atomic emissions over the 
period of time T arising from an initial activity A0 of a radionuclide with a half-life 
of ln(2)/. S is the factor which relates Ã to the delivered Dose. The S-value 
accounts for the energy of the emissions as well as the particular geometry of 
the situation under consideration. S-values are available for establishing the 
absorbed dose to various organs of the body from radioactivity within those 
organs, as well as for establishing the absorbed dose to homogenously filled 
spheres of radioactivity, or even to individual cells. However, appropriate S-
values were not available for the type of in-vitro experiments described in this 
thesis. 
Therefore the use of a Monte Carlo code was investigated for calculating the 
absorbed dose to the cells treated with the radiopharmaceuticals described in 
the preceding section.  
Table 2.2 summarises key properties of some of the Monte Carlo codes more 
frequently applied to Nuclear Medicine.  The class refers to the degree to 
which every possible event is simulated – in the context of microdosimetry, 
class II codes treat knock-on electrons as individual events, whereas in class I 
codes these are grouped.  
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Table 2.2 Key Properties of Several Monte Carlo Codes relevant to Nuclear Medicine 
 
 PARTICLES 
SIMULATED 
ENERGY RANGE CLASS 
EGSNRC ,  1KEV TO 1TEV II 
GEANT ,  > 1KEV II 
PENELOPE 2006 ,  100EV’S TO 1GEV II 
MCNP N,  > 1KEV I 
 
 
It was decided to make use of PENELOPE (Penetration and Energy Loss of 
Photons and Electrons) for all dosimetric calculations. The reasons for this 
principally related to the lower energy range simulated by the code, as well as 
the fact that the system proved to be relatively straight forward to set up on a 
single desktop PC (3GHz Pentium 4 processor, 1GB RAM). For all simulations 
of beta emitting radionuclides, energy spectra were taken from the data used in 
the publication of ICRP report 38 and made available by the Oak Ridge 
Laboratory [69].  
A full appraisal of the application of PENELOPE to measuring the distribution 
of absorbed dose and establishing relevant S-values for use with equation 2.1 
is presented in chapter 3. However, table 2.3 provides an illustration of the 
established relationship between radioactivity and absorbed dose.  
 
 
Table 2.3 Absorbed Dose (Gy) to cells in 6 well plate incubated in 2.5ml RPMI containg 
90
Y-EDTA 
 
 Time after treatment / hrs 
Concentration / MBq/ml 24 48 72 96 120 
0.1 0.6 1.1 1.4 1.7 1.9 
0.2 1.2 2.1 2.9 3.4 3.9 
0.4 2.4 4.3 5.7 6.9 7.8 
1.1 6.6 11.8 15.8 18.9 21.4 
2.2 13.2 23.5 31.6 37.8 42.7 
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2.6 Measuring Response to Irradiation 
A number of different techniques were used to assess the response of cells to 
both EBRT and TRT. For the purposes of cell survival studies, the clonogenic 
assay was used to measure cell survival. Assays of adenosine triphosphate 
(ATP) were used to provide a measure of temporal changes in cell viability 
following treatment.  
Functional responses to irradiation were also investigated. A simple 
luminescence based assay was used to measure apoptosis via the detection of 
caspase effector proteins that form part of the apoptotic pathway. Specific 
molecular pathways were investigated through the use of Western Blot 
techniques.  
2.6.1 Clonogenic Survival Assay 
The clonogenic assay was used as an objective measure of cell survival. The 
assay is based upon observing the ability of single cells to reproduce and 
replicate to the point that a small colony of viable cells is formed. Following 
irradiation, both treated aliquots of cells and a negative untreated control 
aliquot of cells (in triplicate) were serially diluted into 6 well plates, such that 
cells were seeded at 10-1, 10-2, 10-3 and 10-4 concentrations. After a period of 
time (depending on the cell line in question) these well plates were assessed 
for the formation of viable colonies. Colonies were counted relative to the 
negative control sample. If the formation of colonies was not observed for 
treated aliquots at the same concentration of cell seeding as that seen for the 
negative controls, then the relative difference in seeding dilution was taken into 
account. 
 
cellstreated
cellscontrolnegative
cellscontrolnegative
cellstreated
o
dilutionseed
dilutionseed
coloniesn
coloniesn
FractionSurviving
_
__
__
0
_
_
_
_
_
_   
Equation 2.2 
 
Two methods for carrying out this assay were used, depending on the nature 
of the cells. In the case of adherent cell lines (e.g. BT-474, PC-3), colonies 
were assessed as follows. 
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Well plates were placed on ice and the contents washed twice with Phosphate 
Buffer Solution (PBS). Cells were then fixed by adding enough methanol (kept 
at -20°C) to cover the well plate surfaces and left for 10 minutes. After 10 
minutes, the methanol was aspirated and replaced with a 0.5% Crystal Violet 
solution (in 25% methanol) and left for a further 10 minutes. The well plates 
were then rinsed carefully until no colour ran off in solution and left to dry. 
Images of the stained colonies in the well plates were scanned and 
subsequently counted using the ImageJ software.  
In order to support the development of suspension cell colonies (e.g. HL60 and 
MOLT-4) a viscous medium consisting of 50% methylcellulose (3%) Iscove’s 
cell culture media (R&D Systems); 30% FCS; and 20% conditioned HL60 
media, was used to incubate cells. After 2-3 weeks colonies were sufficiently 
well formed to allow visual counting. 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.5 Example of Crytal Violet Stained  PC-3 Prostate Adenocarcinoma Clonogenic Colonies 
grown from A) negative control cells and B) cells treated with 2Gy EBRT. In each case cells were 
seeded at 10
-4
 concentration relative to the treated cells 
 
2.6.2 ATP Viability Assay  
Although clonogenic survival assays were used as an objective end point to 
measure cell death in response to irradiation, an alternative assay was used to 
observe the transient response to irradiation. The CellTiter-Glo® Luminescent 
Cell Viability Assay (Promega Corporation) is a method of determining the 
A) B) 
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number of viable cells in culture based on quantitation of the ATP present, 
which signals the presence of metabolically active cells.  
The assay is sensitive enough to be carried out using 100l samples of a cell 
culture mixed with 100l aliquots of the single reagent in 96-well plates. The 
effect of the reagent is to cause cell lysis, and the production of a luminescent 
signal proportional to the amount of ATP present, which is assumed to be 
directly proportional to the number of viable cells present in the sample. The 
assay uses a proprietary luciferase. The resultant light output signal has a half-
life of approximately 5 hours, although for time course experiments 
measurements were made at a standard time of 20 minutes after mixing.  
The assay was applied to irradiated cell cultures in order to observe changes in 
viability as a function of time, post treatment. Samples were tested prior to 
treatment initiation, 1 hour post treatment initiation and then every 24 hours.  
Samples were taken in duplicate.  
 
2.6.3 Caspase-3/7 Apoptosis Assay 
A similar technique to that described above was used in order to detect and 
measure apoptotic activity. Caspase-3 and caspase-7 are proteins that play an 
important effector role in apoptosis. Activation of caspase-3 in particular, 
occurs at the convergence of the intrinsic and extrinsic pathways [70]. The 
Caspase-Glo® 3/7 Assay (Promega) is an assay that detects these proteins 
using the luciferase reaction. A caspase-3/7 substrate in the reagent is cleaved 
following cell lysis, allowing a luciferase reaction to occur and thus provide a 
light signal that is proportional to the level of caspase-3/7.   As with the ATP 
viability assay, duplicate 100l cell culture samples are mixed with equal 
volumes of the reagent in 96-well plates. The resulting light signal was 
observed to increase for a period of approximately 1 hour following the addition 
of the reagent, before falling off with a relatively long half-life. Hence all 
measures of luminescence were made 1 hour after mixing the cell culture and 
the Caspase-Glo® 3/7 reagent.  
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2.6.4 Western Blots 
Western blotting is a technique which is used to identify specific proteins within 
a particular cell culture. Proteins are separated by size using electrophoresis 
and then transferred to a membrane. Proteins of interest are tagged using an 
antibody specific to that protein, which may then be detected by 
chemiluminescence methods. 
Following incubation with 90Y-EDTA, the 6 well plates containing treated cells 
were placed on ice. The media was removed and the cells washed with ice 
cold PBS. After washing, the cells were detached from the well plates using a 
cell scraper and transferred to Eppendorf tubes. These were spun at 8,000 rpm 
for 10 minutes (4°C). The PBS was aspirated and replaced with 200l cell lysis 
buffer containing 1% protease inhibitor. The tubes were then spun again at 
12,000 rpm for 10 minutes (4°C) and the lysates transferred to further 
Eppendorfs. A luminescence based protein assay (Biorad) was used to assess 
the protein concentration of the lysates. 
A stacking gel was created on top of a bottom gel, between glass plates. 
Polyacrylamide gels were created using the following formations. The bottom 
gel was created using 8ml protogel, 7.5ml resolving gel, 14.2ml distilled water, 
300l 10% ammonium persulphate and 30l TEMED. The stacking gel was 
made up with 2.1ml protogel, 4ml stacking protogel, 9.8ml distilled water, 80l 
10% ammonium persulphate, 80l Bromophenol blue and 16 l TEMED. Wells 
were created by pouring the stacking gel around a plastic comb, before leaving 
the gel to set.  
Cell lysates were prepared for electrophoresis by adding 5l loading buffer and 
heating at 95°C for 3 minutes in order to denature the protein.  
A volume of lysate equivalent to 20g protein was loaded into each well whilst 
one well was set aside for a molecular weight marker. The gels held between 
glass plates were loaded into an electrophoresis tank containing a Sodium 
Dodecyl Suplhate (SDS) running buffer (Tris-Glycine) and run at 150V until the 
molecular weight markers were seen to have separated down the length of the 
gel (~1hr). 
To transfer the proteins, a transfer buffer was made up from 200ml TRIS (no 
SDS) Glycine, 200ml methanol and 1600ml distilled water. The blotting 
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membrane was activated by placing in methanol for 30 seconds, and then 
placed in a tray containing a covering of transfer buffer. Two sheets of 
Whatman paper and sponge, cut to the size of the gels were also placed in the 
buffer, as were the gels themselves. The gel was then assembled next to the 
membrane, held between the sheets of Whatman paper, which were 
themselves held between the sponge. A 200mA current was applied to the 
assembly for 1hr in order to transfer the proteins from the gel to the membrane. 
Following transfer of protein, the membrane was incubated in 10ml 1-2% BSA 
in TBST for 40 minutes, in order to block non-specific uptake of the primary 
antibody. This was followed by overnight incubation at 4°C of the membrane in 
a TBST solution containing 0.3% BSA as well as the primary antibody of 
interest. The following day, the membrane was washed with TBST, before 
incubation with a secondary antibody, appropriate to the nature of the primary 
antibody. After further washes, ECL reagent (GE Healthcare) was applied to 
the membrane, before placing the membrane in contact with photographic film 
within a cassette. Films were kept in contact for standard periods of time in 
order to allow comparison between different membranes. Films were 
developed using an AGFA film developer.        
                                            
Microdosimetry Using PENELOPE 
61  
3 Microdosimetry Using PENELOPE  
 
The aim of this chapter is to appraise and describe the use of the PENELOPE 
Monte Carlo code as a means of providing accurate dosimetry in the context of 
the experiments described in later chapters.  
Following a description of the implementation of PENELOPE used for these 
experiments (chapter 3.1), validation experiments are presented (chapter 3.2), 
both at the macroscopic and microscopic scale, in order to verify the 
techniques used to produce the findings presented later in this chapter. 
Following validation, the PENELOPE code was used to model the absorbed 
dose to cells cultured in multi-well plates, both for the situation in which the 
cells are irradiated by a bound radiopharmaceutical and for the case of cells 
cultured in a radioactive media which does not result in specific uptake. 
Results are primarily presented for the beta emitting isotopes 90Y and 131I, 
taken to be representative of high and low energy beta emitters respectively.  
In chapter 3.3.2, relationships are defined between the absorbed dose to cells 
and both the amount and volume of radioactivity added to these cell cultures. 
These are presented as S-Factors in keeping with the MIRD convention. 
In chapter 3.3.3, the relative influence of radioactivity in neighbouring wells is 
considered. Furthermore, the importance of modelling interactions with the 
Perspex labware itself is presented in chapter 3.3.4.  Chapter 3.3.5 shows the 
results of an investigation on the effect that a non-confluent distribution of cells 
may have on the accuracy of the modelling of dosimetry. 
In chapter 3.4 results are also presented for the modelling of radioactivity 
bound to the surface of tumour spheroids in order to support such 
investigations.  
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3.1  PENELOPE Workflow 
3.1.1 Program Structure 
The PENELOPE Monte Carlo program consists of a set of Fortran subroutines 
designed to simulate different aspects of potential photon / electron 
interactions [71]. Different subroutines address the simulation of different 
physical interactions including both elastic and inelastic scattering (different 
routines cater for photons and electrons) as well as bremsstrahlung radiation. 
Random sampling of the probability distributions is covered by further 
subroutines within this source code. 
In addition to this source code, a number of database files are supplied which 
allow for the generation of files detailing the physical properties of the 
geometry under consideration. In principle data can be generated for any 
arbitrary material although database files describing 280 different materials are 
supplied with the distribution.  
The PENELOPE package also contains three driving programs which can be 
used to direct these subroutines and track the particle simulations in a 
meaningful way. The models used in the following chapter use the PENCYL 
program. This program is based around the definition of cylindrical geometries 
and allows both point source and distributed source arrangements. (The other 
programs PENSLAB and PENMAIN are restricted to point source 
arrangements only and are therefore not suitable for TRT models.) In order to 
run a simulation two input files must be set up by the user. Namely,  
 
 Material Definition File 
 Model Input File 
 
Together, these two files define the specific model to be simulated and 
evaluated. 
3.1.2 Material Definition File 
 
An auxiliary program “material.exe” is included with the PENELOPE 
distribution. When run by the user, this program draws upon a database of 
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atomic interaction data to define a file containing all relevant information (such 
as cross-sections for particular radiation interactions) for each material 
specified. The resulting datafiles are then concatenated to produce a single file 
containing all necessary data for the simulation.  
3.1.3 Model Input File 
A model input file must be defined by the user. The principal components of 
this file are as follows: -  
 Model geometry 
 Nature of source radiation (gamma / electron) 
 Energy spectrum of source radiation 
 Distribution of source radiation 
 Specification of the material definition file to be used. 
 Simulation parameters (e.g cut-off energies) 
 Specification of the geometric elements of interest. 
 
Firstly, the geometry is defined by a set of cylinders or annuli which are 
assigned an axial thickness, inner and outer radius and a material. No overlap 
of these geometric elements is permitted. 
The source radiation is defined by a number of parameters. First the nature of 
the radiation (photons, electrons or positrons) is specified. Therefore in order to 
simulate radionuclides that emit both electrons and photons it is necessary to 
run separate simulations.  
The energy distribution of the photons/ electrons is defined either as being 
monoenergetic or as a spectrum described in terms of energy bins and relative 
probability of emission for a given bin. The source position may be defined as a 
point with a given position. Alternatively any number of the defined geometrical 
elements may be assigned as being “radioactive”. If desired, the relative 
activity of these elements to each other may also be defined. Otherwise, the 
probability of emission is assumed to be equal between all assigned bodies.  
The third part of the input file specifies the number of different materials 
involved in the simulation and points towards the specifically generated 
material file that contains all the necessary information for the simulation. 
Furthermore, a cut-off energy below which particles are no longer explicitly 
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tracked must be specified for each material. The remainder of the input file 
determines details of the way in which the output data are formatted for 
interpretation and analysis, and is further described in the next section.  
 
3.1.4 Dosimetry Output 
The purpose of running the PENELOPE Monte Carlo simulations was to derive 
S-factors that could be applied to specific in-vitro situations.  
Information regarding the deposition of energy within the geometric model is 
specified in a number of ways. Altogether, the PENCYL program produces a 
number of data files which describe the nature of the charge and energy 
distribution throughout the simulation in different ways. However, for the 
purposes of the model evaluation, the following output files were used most 
extensively and are described in more detail below. 
 
 Pencyl output summary file (pencylres.dat) 
 3D absorbed dose distribution data (pc-dosc1.dat) 
 Depth absorbed dose distribution (pc-ddose.dat) 
 
The pencylres.dat file provides an overview of the energy deposition across the 
whole model. For each geometric cylinder or annulus defined in the model 
input file, the energy absorbed per primary particle is reported in eV. 
Furthermore a breakdown is provided of the number of primary particles 
simulated and the fate of those particles in terms of whether they are absorbed, 
transmitted or backscattered into the geometric element that is their source. 
Further data are provided on the nature and number of the simulated collisions 
of secondary particles. 
However, depending on the size of the geometric elements this may not 
necessarily provide information on a microscopic scale. The pc-dosc1.dat 
output files provided absorbed dose distributions (in eV/g) for specified bodies 
as a function of both the axial position (z) and the radius from the geometric 
centre (r). This data was provided in both a graphical form, as well as a 
tabulated form to allow further analysis of the data. Alternatively, the ddose.dat 
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files provided an axial absorbed dose profile averaged over the radial plane of 
the model throughout all geometric bodies. 
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3.2 Validation of PENELOPE Model 
 
Radiation exposures made using the 137Cs blood irradiator were measured in 
situ in order to confirm that the expected absorbed dose was delivered. In the 
case of experiments simulating TRT, the microscopic scale of the geometries 
involved meant it was not possible to make in situ measurements in order to 
verify the prediction of absorbed dose to radio-labelled cells, or even to cells 
bathed in a radioactive media. Therefore two validation exercises were carried 
out whereby PENELOPE simulations were tested against reference datasets. 
The first validation exercise involved the testing of macroscopic models against 
reference datasets, whilst the second validation was carried out at the 
microscopic scale. 
 
3.2.1 MIRD Sphere Self-Dose  
Calculations have been made and published detailing the radiation dose 
absorbed by different sized homogenous spherical distributions of a number of 
radionuclides. These are specified in terms of S-Factors [72].  
Therefore in order to verify the implementation of PENELOPE, a number of 
simulations were run. Each simulation consisted of a cylinder of water 
uniformly filled with radioactivity - either 90Y or 131I – surrounded by a volume of 
air. In order to match the spherical geometry as closely as possible, the 
diameter and height of the cylinders were kept equal. The mass of these 
cylinders were 0.02g; 0.1g; 0.8g; 20g; 100g; 400g; 800g; and 3kg. Simulations 
were performed using 10 million primary electrons. Particles were tracked 
down to a minimum energy of 1keV. 
The dosimetry information written to the pencylres.dat files was expressed as 
the energy deposited per primary particle. A conversion to an S-Factor 
(mGy/MBq-s) was made as outlined in Appendix 1. 
As shown in figures 3.1 these derived S-Factors compare favourably with the 
published MIRD data on self-dose to small uniform spheres and no significant 
difference was found between the MIRD datasets and the PENELOPE 
simulations for either 90Y or 131I (r2=0.99).  
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Figure 3.1 Comparison of PENELOPE Dosimetry vs published MIRD Dosimetry of Uniformly 
Filled Spheres of Radioactivity for A) Y-90, B) I-131. Uncertainties are too small to be visulised. 
 
The results of this validation indicate both a correct setup of the PENELOPE 
input files and subsequent interpretation of the PENELOPE data output. 
Initially, a closer correlation between the MIRD reference values and the 
A) 
B) 
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PENELOPE cylindrical models was observed for the 90Y data compared to the 
131I data. However, it should be noted that the simulations of 131I did not initially 
include the modelling of absorbed dose deposition from the photon emissions 
of this radionuclide. The significance of this omission becomes greater at the 
larger volumes considered (see figure 3.2). Inclusion of the photon component 
resolves the differences observed. The photon contribution becomes 
increasingly less significant at smaller volumes, a situation more relevant to the 
scale of in-vitro experiments. However, it is interesting to note that energy 
deposition from photon emissions is of the order of 10% for a volume of 20ml 
and could potentially need to be taken into account when deriving S-Factors for 
in-vitro experiments at larger scales.  
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Figure 3.2 Relative Energy Deposition in Water Sphere Uniformly Filled  with I-131 
 
The non-linear nature of the S-Factor reciprocal vs mass relationship for 90Y is 
explained when consideration is given to the average energy absorbed by the 
water volume, per primary particle emitted. If all the beta particles emitted were 
absorbed within the source element of the model then this figure would simply 
be equivalent to the average energy of the beta spectrum simulated.  
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However, it can be conceived that emissions occurring near the edge of the 
volume would scatter or progress out of the source element and would 
therefore not be absorbed by the source itself. As the energy (and therefore 
the range) of the emissions increased, this would become a more significant 
effect.  
As illustrated in figure 3.3, the higher energy 90Y beta emissions have a higher 
probability of escaping the source element than those of 131I as the volume 
considered is reduced.  
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Figure 3.3 Energy Deposition as a function of Uniform Sphere Size 
 
Microdosimetry Using PENELOPE 
70  
3.2.2 Point Source Kernel 
In order to validate the performance and correct interpretation of PENELOPE 
simulations at the microscopic scale, simulations were made of a point source 
of 90Y surrounded by water. A geometric model of a point source of 90Y 
surrounded 5cm of water in any direction was created. The absorbed dose 
deposited along the radial axis of the model was scored at intervals of 9m 
between 0m and 198m and at intervals of 220m from 198m to 1cm 
(figure 3.4). (In order to score the energy deposition at these intervals two 
concentric cylinders were modelled, r 0→198m and r=198→10,000m 
respectively, surrounded by a third with radius 5cm). Data was obtained from 
the 3D absorbed dose distribution tabulation described in section 3.1.4.  
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Figure 3.4 Radial Profile of Absorbed Dose Deposition Arising from a 
90
Y Point Source in Water 
 
As shown, the absorbed dose varies rapidly as a function of distance over 
several orders of magnitude.  
Therefore, the normal convention when presenting dose point kernels is to 
make use of a dimensionless scaled dose kernel [73]. 
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Equation 3.1 Scaled dose kernel 
 
X90 is the distance at which 90% of the energy emitted has been absorbed by 
the surrounding material (5.4mm); E is the average energy of the beta 
emission spectrum (0.934MeV). The purpose of the scaled dose kernel is to 
facilitate comparison between other isotopes as well as monoenergetic 
electron sources. Figure 3.5 shows the scaled dose kernel obtained from the 
model described overlaid on reference data previously published for the same 
dose kernel [73]. 
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Figure 3.5 Scaled Point Dose Kernel for Y-90 Derived Using PENELOPE 
 
The point dose kernel derived from the PENELOPE data shows a close 
association with the EGSnrc data previously published. Minor deviations occur 
at the transition between the inner cylindrical body and the outer, as well as at 
the singularity where r = 0. Further comparisons with published dose point 
kernels are made in chapter 3.5. 
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Figure 3.6 Comparison of Radial and Axial Dose Profile from PENELOPE Simulation of 
90
Y Point 
Source. 
 
The radial absorbed dose profile was also compared with an axial absorbed 
dose profile in order to check the isotropic performance of the PENELOPE 
code. This comparison is shown in figure 3.6 and demonstrates that absorbed 
dose profiles can be measured along either the z-axis or the radial axis of a 
given model, although there is less uncertainty associated with the radial 
profiles. 
The purpose of the two validation experiments was primarily to give confidence 
in subsequent dosimetry models developed for the purpose of the dose-
response experiments described in the following chapters, and specifically the 
way in which output from PENELOPE has been interpreted.  
The validation of absorbed dose to uniform volumes of activity as described in 
3.2.1 primarily provides confidence in the correct set up of the model input files, 
particularly with respect to the definition of the energy spectra, the description 
of the radioactivity deposition and the material specification. 
The simulation of the point source provides further confidence in the simulation 
of the underlying physics as well as the way in which the output data are 
analysed and processed.  
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3.3 Dosimetry of Multi-Well Plates 
  
For the purposes of the experiments described in the remainder of this thesis, 
S-Factors were required predominantly for 6 well plates. However, the 
dosimetry of standard 12, 24, 48 and 96 well plates is also considered.  
The aim of this section is to present the results of this work and moreover to 
investigate whether a universal set of S-Factors could be derived for in-vitro 
investigations of TRT that would avoid the need for future Monte Carlo 
modelling of each individual situation that could arise.  
 
3.3.1 Modelling of Cell Culture Well Plates 
As well as using 90Y-EDTA as a means of providing low dose-rate irradiation to 
cell cultures, it was also anticipated that experiments would be carried out 
using a radio-labelled antibody or peptide as a more realistic model of targeted 
radionuclide therapy.  Therefore, two distinct situations were considered with 
respect to in-vitro cell culture experiments: the first was that of a monolayer of 
cells incubated with homogenously radioactive cell culture media; the second 
was that of a monolayer of cells incorporating a bound radiopharmaceutical 
incubated in non-radioactive cell culture media (See figure 3.7).  
The materials.exe program was used to define PENELOPE material files for 
polystyrene (to model the cell culture flasks); air; water (for cells and cell 
culture media); and iron (to model the steel shelf of the incubator). These were 
then concatenated into a single file for use with these simulations.  
Both the situations outlined above were simulated for 6, 12, 24, 48 and 96 well 
plates. The dimensions used to describe the geometry are shown in table 3.1. 
In the case of a monolayer of cells incorporating a radiopharmaceutical, a finite 
dimension must be assigned to the height of the radioactive element of the 
model. Cells can vary in size from as small as 5m diameter up to 100m 
diameter. However, the majority of cells are of the order of 10m diameter so 
this was used as the height of the radioactive layer. The thickness of the steel 
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shelf upon which the well plates were placed whilst in incubation was set to 
2mm. 
 
Figure 3.7 Schematic Diagram of Cylindrical Geometries Used to Simulate Dose Deposition to Cell 
Cultures in Multiwell Plates for the Situation of A) Uniformly Radioactive Cell Culture Media and 
B) A Monolayer of Cells With Radiopharmaceutical Uptake 
 
 
NUMBER OF 
WELLS 
WELL 
DIAMETER / 
MM 
POLYSTYRENE 
THICKNESS / 
MM 
MAXIMUM 
VOLUME / ML 
VOLUME 
MODELLED 
/ ML 
HEIGHT OF 
WATER 
COMPONENT 
/ CM 
6 35.4 
1.3 
16.8 2.5 0.25 
12 22.7 6.9 1 0.25 
24 16.3 1.90 0.5 0.26 
48 11.6 0.95 0.3 0.29 
96 6.86 0.36 0.1 0.27 
Table 3.1 Specification of Plastic Cell Culture Labware 
 
 
Figure 3.8 shows the average energy absorbed per primary electron simulated, 
for the above models in the cases of both 90Y and 131I. As with the validation 
experiments described in chapter 3.2.1 this should be no more than the 
average energy of the respective beta energy spectra.  
When any dimension of the volume considered is less than the range of the 
beta particles, this results in a significant number of particles escaping the 
target volume and hence a fall in the absorbed energy. This is most clearly 
observed with 90Y. When the activity was restricted to a 10m layer then this 
effect is even more pronounced.  
■ Perspex   ■ Water 
■ Radioactive Water ■ Air 
■ Iron 
 
 
A) B) 
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Figure 3.8 Energy Deposition in Multiwell Plates for A) 
90
Y and B) 
131
I 
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3.3.2 Absorbed Dose Distribution to Cells 
Due to the finite range of both beta and secondary electrons, cells at the edges 
of the wells receive a lower absorbed dose than those at the centre (see figure 
3.9). Therefore consideration must be given to the distribution of absorbed 
dose over the area of the well plates.  
 
 
 
 
 
Figure 3.9 Dose Distribution Across 6 Well Plate From Uniform Distribution of a) 
90
Y and b) 
131
I 
 
A) 
B) 
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The absorbed dose distribution along the surface of the well plate can be 
analysed to provide both a conventional histogram of absorbed dose over the 
area of the plate as well as a dose volume histogram showing the dose 
absorbed over a given volume. (See figure 3.10-3.13)  
These show how a radionuclide with lower energy emissions such as 131I is 
much more likely to achieve a consistent absorbed dose over the whole cell 
population than a higher energy beta emitter such as 90Y.  
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Figure 3.10 Cumulative Dose Volume Histogram Resulting From Uniform Distribution of 
Radioactivity in Multiwell Plates 
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Figure 3.11 Differential Histogram of Absorbed Dose Resulting From Uniform Distribution of 
Radioactivity in Multiwell Plates 
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Figure 3.12 Cumulative Dose Volume Histogram Resulting From Bound Monolayer Distribution 
of Radioactivity in Multiwell Plates 
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Figure 3.13 Differential Histogram of Absorbed Dose Resulting From Bound Monolayer 
Distribution of Radioactivity in Multiwell Plates 
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The 3D absorbed dose distribution outputs were analysed to provide dose 
volume histograms of absorbed dose in the case of radioactive media and cell 
bound radioactivity (see figure 3.10 and 3.12). These were then modified to 
provide a histogram of absorbed dose over the volume considered to be 
occupied by a layer of cells. (See figures 3.11 and 3.13.) 
As the size of the well plate considered is reduced and energy losses at the 
edges of the wells become more important, there is increasingly a spread in 
the distribution of absorbed dose over the area of that well, especially in the 
case of 90Y.  
The histograms of absorbed dose were fitted with a Gaussian model, in order 
to provide a single value (along with an appropriate uncertainty) for the 
absorbed dose per primary particle emitted. (The histograms are not always 
symmetrical – in such cases the Gaussian model provides a more appropriate 
description of the absorbed dose than the mean.) These values were 
converted to S-Factors as outlined in Appendix 1 and are presented in tables 
3.2 and 3.3. 
 
ISOTOPE 6 WELL 
(2.5ML) 
12 WELL 
(1ML) 
24 WELL 
(0.5ML) 
48 WELL 
(300L) 
96 WELL 
(100L) 
90Y 0.0264±0.0004 0.061±0.001 0.12±0.01 0.113±0.02 0.48±0.09 
131I 0.0071±0.0001 0.0165±0.0005 0.033±0.001 0.0665±0.001 0.185±0.005 
Table 3.2 S-Factors for Dose to Cells in Uniformly Radioactive Cell Culture (mGy/MBq-s) 
 
 
ISOTOPE 6 WELL 
(2.5ML) 
12 WELL 
(1ML) 
24 WELL 
(0.5ML) 
48 WELL 
(300L) 
96 WELL 
(100L) 
90Y 0.103±0.004 0.238±0.016 0.472±0.03 0.887±0.06 2.46±0.18 
131I 0.117±0.007 0.272±0.016 0.534±0.03 1.04±0.08 2.97±0.25 
Table 3.3 S-Factors for Dose to Monolayer of Cells Resulting from a Bound Radiopharmaceutical 
(mGy/MBq-s) 
 
The tables above enabling the calculation of absorbed dose have been derived 
in relation to specific volumes of cell cultures.  Nonetheless, in the case of a 
monolayer of bound radiopharmaceutical, the absorbed dose delivered will be 
largely independent of the volume of cell culture media. (However, the 
thickness of the layer representing the monolayer of cells can have a 
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significant impact on the magnitude of the S-Factors. When the thickness of 
the layer was set to be 50m rather than 10m, then the calculation of 
absorbed dose was decreased by 25% for 90Y and 50% for 131I.) 
In the case of a uniformly radioactive cell culture, the volume of cell culture 
media added will have a significant effect on the absorbed dose. If the total 
energy (per primary electron) absorbed within the cell culture media remained 
constant then S-Factors for any volume could be calculated relative to the 
reference data presented in table 3.2 using equation 1.1. As figure 3.14 
illustrates though, this is not the case.  
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Figure 3.14 Average energy absorbed as a function of cell culture media volume in 6 well plate 
 
As the height of the active volume is reduced below the range of the beta 
particles, the energy absorbed by the cell culture media falls sharply. This 
relationship was analysed and empirically found to be described by the 
following equation. 
 
 xk
xE
E

 0  
Equation 3.2 
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Eo is close to the average energy of the emission spectrum; the difference is 
due to the fact some energy will always be absorbed by the well plate bottom 
and sides. The parameter k relates to both the range of the beta particles and 
to the geometry under consideration, whilst x is the height of the cell culture 
media.  
However, the above curve describes the energy absorbed over the whole 
volume and relates to the average absorbed dose over the whole volume. If 
the absorbed dose across the bottom of the well (derived from the dose 
histograms) is multiplied by the volume of the well, then similar curves are 
derived, which can be fitted with the type of function described in equation 3.2. 
Thus, the absorbed dose per primary particle to any volume of radioactivity can 
be defined by the following expression. 
 
 
  





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VE
V
D
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Equation 3.3 
 
Values of E0, and k specific to combinations of well plates and isotopes are 
presented in the table 3.4.  
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Isotope Well Plate E0 k 
90Y 96 4.3x105 0.10 
48 5.4x105 0.12 
24 5.8x105 0.13 
12 5.0x105 0.10 
6 5.4x105 0.12 
131I 96 1.4x105 0.07 
48 1.4x105 0.07 
24 1.4x105 0.06 
12 1.4x105 0.06 
6 1.1x105 0.02 
Table 3.4 Parameters for determining absorbed dose to cells incubated in a arbritary volume of 
radioactivity. (Dose given as eV/g per unit cumulative activity.) 
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Figure 3.15 Accuracy of Empirical Dose Estimate 
 
The figure above shows the accuracy of these empirical calculations of 
absorbed dose for any given volume of activity, in comparison with the results 
of the PENELOPE simulations of defined cell culture volumes.  
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3.3.3 Investigation of the absorbed dose to adjacent wells 
One of the limitations of the pencyl program is the fact that only cylindrical 
geometries can be modelled. Therefore all of the models consider only a single 
well. An important question to answer from a practical point of view is whether 
activity within one well can give rise to an unaccounted radiation dose in a 
neighbouring well. i.e. can single wells in a multi-well plate be considered as 
being independent of their neighbours? 
Although the cylindrical constraints of pencyl prevent a direct simulation of the 
situation, it was possible to analyse the models of the single wells to explore 
the potential absorbed dose from one radioactive well to its neighbour.  
 
 
Figure 3.16 Absorption of Energy Emitted by 
131
I in a Single Well 
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Figure 3.17 Absorption of Energy Emitted by 
90
Y in a Single Well 
 
 
If the energies per primary particle absorbed by all components of the model 
are considered then it possible to estimate how many electrons have 
“escaped” the simulation of a single well. In the case of 131I these losses are 
less than 1% of the average energy of the beta spectrum (figure 3.16). 
Therefore it can be concluded that the polystyrene of the labware is sufficient 
to absorb the beta emissions of 131I and that cells in neighbouring wells will not 
receive any significant radiation dose for which dosimetry information is 
unavailable. 
However, in the case of 90Y it can be seen that approximately 10% of the 
energy emitted is unaccounted for (figure 3.17). Although this energy would be 
emitted isotropically and that one would therefore assume that the solid angle 
subtended by a layer of cells in an adjacent well would render the absorbed 
dose to these cells insignificant, a further simulation was run to confirm this 
was the case. The existing model was extended as shown in figure 3.18.  
Microdosimetry Using PENELOPE 
88  
In order to model the “worst-case” scenario, the model was based upon the 
dimensions of the 96 well plate, and neighbouring wells were considered to be 
in immediate proximity to the active well with no air gap.  
 
  
 
Figure 3.18 Geometric Model Used to Investigate Dose to Adjacent Wells 
 
The results of the simulation demonstrated that the absorbed dose per primary 
particle to the radioactive water was 3.81x106eV/g compared with 
2.36x104eV/g delivered to the surrounding water. i.e. the absorbed dose from 
one well to its neighbour can be considered to be <1% of the absorbed dose 
absorbed by that well. 
 
3.3.4 Influence of Polystyrene 
Attempts have been made to calculate dosimetry factors for in-vitro work based 
upon published data considering the spherical models described earlier. Such 
approaches do not take interactions within the polystyrene labware itself into 
account. Moreover, the thickness of the polystyrene was modelled as being 
1.3mm, a value which was specific to the equipment used in this laboratory but 
may not be true across all manufacturers. 
The aim of the following section was to investigate to what extent the 
surroundings of a radioactive source representing an in-vitro experimental 
investigation need to be considered.  
■ Perspex   ■ Water 
■ Radioactive Water ■ Air 
■ Iron 
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In the first instance, the simulation of radioactivity in a 6 well plate was 
repeated for the case of homogenously radioactive water. However, the 
polystyrene and iron components of the model were designated as air. This 
resulted in a reduction in absorbed energy within the water of 3.3% and 0.6% 
for 90Y and 131I respectively. However, this represents the difference in the 
average energy absorbed throughout the whole volume of water. 
Consideration must be given to the fact that although cell culture media may be 
produced that is uniformly radioactive, the cells themselves will lie on the 
bottom surface of the well plate. i.e. the area in which backscatter is likely to 
have the most significant impact. 
If the axial absorbed dose profile is considered for the case of the simulation 
consisting solely of water and air compartments then it is observed to be 
symmetrical around the centre of the water component of the model (see figure 
3.19). In this situation there is no backscatter of radiation into the water. In the 
situation for which the plastic of the labware is included, then it can be seen 
that the profile becomes asymmetric, presumably due to the addition of 
backscatter from the polystyrene into the water. In fact, at the bottom of the 
well plate there is a 25% increase in the dose absorbed when the polystyrene 
labware is accurately modelled in the case of 90Y and 13% in the case of 131I. 
The replacement of polystyrene and iron components by air was also applied 
to the model described in figure 3.7b, used to simulate a monolayer of 
radiolabelled cells. In this case reductions of 23.1% and 11.1% in absorbed 
energy were observed for 90Y and 131I respectively. 
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Figure 3.19 Axial Profile of Absorbed Dose Delivered to Uniformly Radioactive Water in 6 Well 
Plate from A) 90Y and B) 131I 
 
B) 
A) 
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Therefore it would appear that modelling the backscatter of electrons at the 
water polystyrene interface can make a considerable difference to the 
dosimetry of cell cultures, particularly for higher energy beta emitters.  
This then leads to a further question as to whether the thickness of the 
polystyrene is of any significance regarding the magnitude of the backscatter. 
In order to explore this further, a series of simulations were run in which the 
thickness of the polystyrene layer was successively reduced from 1.3mm to 
10m (see figure 3.20). Initially it was anticipated that this would lead to a 
reduction in the absorbed energy, towards the result of the models using only 
water and air. However, for both 90Y and 131I this was not the case. From this, 
one can infer that there is also a large degree of backscattered radiation from 
the iron shelf of the incubator that becomes more significant as the attenuating 
property of the polystyrene is reduced. Indeed, when the simulations were 
repeated for the case of a 1.0m thick iron shelf the expected trend was 
observed.  
The magnitude of the energy absorbed appears to be more sensitive to 
changes in the thickness of the polystyrene in the case of 90Y. The results 
suggest that 131I beta emissions will backscatter from depths of up to 0.1mm in 
polystyrene plastic. The higher energy 90Y emissions will backscatter from 
depths of up to 0.5mm. i.e. as long as the labware in which cells are cultured in 
thicker than 0.5mm then the S-Factors presented in 3.3.2 may be considered  
as universally applicable to all manufacturers.  
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Figure 3.20 Dose Absorbed by Radioactive Monolayer as a Function of Plastic And Iron Thickness 
for A) 
90
Y and B) 
131
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3.3.5 Non-Confluent Cell Distributions 
Two distinct situations have already been modelled. Firstly, a situation in which 
cells are exposed to a radioactive cell culture media whilst in the second case 
the radioactivity is not free in the cell culture media, but is instead attached to 
the monolayer of cells via an appropriate radiopharmaceutical.  
However, it is worth considering that not all cell lines will grow as a continuous 
sheet of cells or reach full confluence. In the case of cells exposed to a 
radioactive media, the absorbed dose is not a function of the cell distribution. 
However, in the case of cells which incorporate a radiopharmaceutical, it can 
be seen that the distribution of the cells over the well plate surface needs to be 
considered. 
For example if a short range (< 10m) emitter is incorporated into a 50% 
confluent cell culture, then the model described in chapter 3.3.1 will 
underestimate the absorbed dose by a factor of 2. (The energy emitted will be 
considered over the whole surface area of the well plate. In reality the energy 
is restricted to cells covering half that surface area meaning that the radiation 
intensity will be twice as high.) 
For medium range beta emitters a proportion of the energy emitted will not be 
absorbed by cells but will instead be deposited between cell clusters due to the 
crossfire effect. This proportion is likely to be a function of the distance 
between cell clusters as well as the energy of the beta emissions. 
Specifically, in the case of the BT-474 breast carcinoma cell line, the cells do 
not grow to 100% confluence, but instead grow in adherent patches as 
illustrated in figure 3.21 to a maximum of ~50% confluence.  
To investigate the dosimetry of such a non-confluent cell distribution, the model 
previously used to simulate a radioactive monolayer in a 6 well plate was 
modified as follows. The radioactive water layer was modified such that the 
layer was defined by a number of concentric cylinders which were alternately 
designated as being radioactive or non-radioactive. The width of the rings was 
varied to simulate varying sized cell clusters and varying distances between 
them. Simulations were carried out of 131I emissions (beta spectrum only) as 
well as for 90Y.  
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Figure 3.21 BT-474 cells at 50% confluence 
 
 
As anticipated, for the case of 131I when 50% of the well surface area is 
covered by cell clusters separated by a large distance relative to the range of 
the beta particles, the absorbed dose to the cells per emission is nearly twice 
as high as when the cells are evenly distributed over the entire surface area. 
However, as can be seen in figure 3.22, the finite range of the beta particles 
results in energy losses to the volume between the cell clusters, resulting in a 
reduction of the absorbed dose at the edges of these clusters. 
As the size of the clusters and the distance between them is reduced, an 
increasingly high proportion of cells will find themselves near such edges and 
as a consequence the absorbed dose per emission decreases. However, even 
for cell clusters as small (and close) as 100m, the absorbed dose is still up to 
50% higher than is the case for a confluent distribution. 
For 90Y emissions which have a higher energy than those of 131I, the same 
initial result is seen whereby for 1.7mm cell clusters, the maximum dose-rate is 
twice that calculated in the original simulation of a confluent layer. There is 
however, a much faster tendency for the dose distribution to approach that 
associated with an even distribution of radioactivity as the separation of cell 
clusters is reduced.  
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Figure 3.22 Radial Profile of Absorbed Dose to Concentric Arrangement of Alternatively 
Radioactive and Non-Radioactive Cells in 6 well plate for A) I-131 and B) Y-90 
 
 
(In the case of the BT-474 cells treated with 90Y-Herceptin an alternative S-
Factor was used based upon an assumption of 50% confluence and a cluster 
size of 100-200m.) 
 
B) 
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3.4 Dosimetry of Multicellular Spheroids 
Multicellular spheroids are a commonly used in-vitro model of micro-
metastases in cancer studies [74, 75]. Although chapter 3.2.1 discussed the 
dosimetry of uniformly radioactive spheres, the in-vitro application of 
radiopharmaceuticals to such spheroids will not necessarily result in such a 
distribution of radioactivity. Instead the radiopharmaceutical is more likely to 
bind to the surface of the spheroid resulting in a heterogeneous absorbed dose 
distribution over the spheroid. 
In order to assess the likely absorbed dose distribution across such spheroids, 
geometric models were created for use with PENCYL as follows. Spherical 
geometries were created using a stack of cylinders of diameters such that they 
formed an approximately spherical volume as shown in figure 3.23.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.23 Stack of cylinders arranged to approximate a spherical volume 
 
In terms of defining the material composition, all cylinders were designated as 
water as was the media around the spheroid. Radioactivity was assigned to the 
outer 5% of each cylinder. The figure of 5% was chosen to represent some 
diffusion of radioactivity from the outer edge of the spheroids as has been 
observed in some experimental models [76].  
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A detailed assessment of absorbed dose over the central cylinder with a 
diameter equivalent to the diameter of the spheroid was made in order to 
obtain radial profiles of the absorbed dose over the whole volume. Studies 
were made of the dose distribution resulting from 90Y, 131I and phosphor-32 
(32P) in spheroids of 5mm, 1mm, 0.5mm and 0.1mm radius. (A radius of 5mm 
is clearly unlikely for an in-vitro cell spheroid – however such a spheroid was 
considered as it represented a distance approaching the maximum range of 
the 90Y beta particles.) 
As the energy of the beta emissions decreases (90Y Emax= 2.28MeV; 
32P Emax= 
1.71MeV; 131I Emax= 0.606MeV) the decreased range of the electrons means 
that dose deposition becomes increasingly confined to the outer zone of the 
spheroid. (See figure 3.24.) In all cases the absorbed dose deposited per 
primary emission increases dramatically as the radius of the spheroid 
decreases, since the emissions are effectively limited to an increasingly 
confined volume.  
The total number of emissions of course depends upon the amount of 
radioactivity taken up by the cells making up the spheroid. In the case of a non-
internalised antibody or peptide it seems reasonable to assume that this will be 
proportional to the surface area of the spheroid.  
Therefore figure 3.25 shows dose volume histograms for the case where the 
absorbed dose distribution throughout the 1mm, 0.5mm and 0.1mm radius 
spheroids has been normalised to the case of the 5mm radius spheroid. 
In the case of an 131I labelled spheroid, the absorbed dose absorbed over the 
volume of the entire spheroid increases as the size of the spheroid considered 
decreases. Initially this is true of both a 32P and a 90Y labelled spheroid. 
However, in the case of these two isotopes the results suggest that for 
spheroids of 1mm or less radius, the dose distribution will be the same 
regardless of the size of the spheroid.  
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Figure 3.24 Radial dose profile to spheroids resulting from radionuclides localised over surface of 
spheroids 
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Figure 3.25 Dose Volume Histograms for Various Sized Spheroids 
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3.5 Discussion 
The issue of dosimetry is crucial to establishing reproducible and meaningful 
dose-response relationships, whether in the context of clinical treatment 
planning studies or in in-vitro studies such as those presented in this thesis.  
At the clinical level, there have been numerous publications detailing methods 
to convert both planar [77] and/or tomographic image data into assessments of 
absorbed dose. To date there have been several implementations of the 
conversion of SPECT activity distributions to absorbed dose distributions using 
both kernel techniques [78, 79] or direct Monte Carlo simulation [38, 80, 81].  
As discussed previously, kernel techniques involve the convolution of the 
absorbed dose distribution around a point source with the spatial distribution of 
radioactivity. Originally dose point-kernels for monoenergetic electrons were 
derived analytically by Spencer [82]. These were then subsequently averaged 
over the spectrum of various commonly used radionuclides to produce dose 
point-kernels appropriate for applications in nuclear medicine [83]. The first 
application of Monte Carlo to monoenergetic dose point-kernels was published 
by Berger et al in 1971 using ETRAN [84]. Various refinements have 
subsequently been published as new codes are released or old codes updated, 
including dose point-kernels for beta emitting radionuclides [85-87].   To date 
these kernels have generally been produced by either the Electron Gamma 
Shower (EGS) or by the Monte Carlo N-Particle (MCNP) codes. A comparison 
of dose point-kernels produced using either EGSnrc, MCNP or GEANT4 
published by Pacilio et al concluded there was relatively little difference 
between them for higher energy beta emitters such as 90Y or 188Re. For 131I 
discrepancies for low energy electrons led to differences of ~10% at short 
source to target distances [88]. Uusijärvi et al carried out a similar exercise 
comparing the PENELOPE code to GEANT4, MCNP and ETRAN [89]. In their 
evaluation of monoenergetic point dose-kernels they observed average 
differences of <10% for energies ranging from 10keV to 1MeV. The 90Y point 
dose-kernel presented in figure 3.5 is overlaid in figure 3.26 onto data 
presented by Mainegra-Hing et al [73] showing the point dose-kernel they 
derived using EGSnrc as well as both the analytical kernel produced by 
Prestwich et al and the first publication of a Monte Carlo derived kernel by 
Berger. 
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PENELOPE
 
Figure 3.26 Penelope data overlaid on excerpt from Mainegra-Hine et al [73] 
 
As can be seen the data produced as a validation of the implementation of 
PENELOPE used in this chapter is most closely matched to the more recent 
EGSnrc / EGS4 derived kernels. 
At the microscopic level, the dosimetry of single cells has been more 
extensively studied compared to the situation regarding multicellular 
arrangements. In general the MIRD approach has been taken to dosimetry of 
single cells, but rather than defining source and target organs, cellular 
compartments such as the nucleus and cytoplasm are used. As with dose 
point-kernels analytic approaches were originally used to define relationships 
between the absorbed dose to a target compartment of a cell and the 
cumulative activity in source compartments [31]. These have subsequently 
been compared to calculations based upon Monte Carlo codes [90-92]. The 
primary application of such single cell models has been towards dosimetry 
calculations involving Auger emitting radionuclides, for which the range of the 
particles is of the order of the cell dimensions [93, 94]. 
Although the case of a single cell and beta emitting radionuclides has also 
been considered, models of absorbed dose distribution in multicellular 
situations accounting for cross fire have also been described.  
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The major application of these models has been to explore the consequences 
of radiopharmaceutical heterogeneity at the microscopic scale [95, 96]. For 
example, Hindie et al have considered the microstructure of thyroid follicles 
and demonstrated differences of ~10% between the average absorbed dose to 
the thyroid and the absorbed dose delivered to the thyroid cells themselves 
[97]. Zhu et al considered the microdosimetry of tumour cells targeted by 
radiopharmaceuticals localised to endothelial cells within tumour vasculature in 
order to objectively optimise the potential choice of radionuclide [98]. This type 
of approach is analogous to that presented in chapter 3.3.5 in which the effect 
of a non-confluent cell distribution on the absorbed dose to those cells was 
shown to be up to 100%. In common with the literature, it is demonstrated that 
this is an effect that is even more pronounced for lower energy beta emissions. 
Nonetheless, even for cell clusters regularly spaced at 0.44mm (~5% of the 90Y 
maximum beta particle range) this leads to a difference of ~50% between the 
absorbed dose calculated on the assumption of a continuous distribution of 
radioactivity and that when the heterogeneity is accounted for. 
The distribution of cells within a tissue culture flask is of course a somewhat 
simpler biological situation than those discussed above. Nonetheless, for many 
in-vitro experiments involving radionuclides, absorbed dose may be expressed 
in surrogate units such as radioactivity concentration, making comparison with 
EBRT treatments difficult. The only publication to date of S-Factors for use in 
multi-well plate experiments was published by Freudenberg et al [99]. They 
used a convolution technique to calculate absorbed dose within the wells, 
based upon the dose kernel of Prestwich. It is important to note that such an 
approach will not account for interactions within the well plate itself and that as 
presented in chapter 3.3.4, for high energy beta emitters, neglecting to 
consider these interactions may lead to errors of ~25% in the calculation of 
absorbed dose. Indeed, comparison of their results with those presented in this 
thesis, reveal differences of -17% and -20% in the dosimetry of 6 well plates 
containing 90Y and 131I respectively.  
The dosimetry of multicellular spheroids was originally discussed in the context 
of theoretical discussions of the most appropriate radionuclides to be used in 
the treatment of micro-metastases [53, 100]. The analysis of these situations 
tended to assume a homogenous distribution of the radionuclide throughout 
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the spheroid. The general findings of these investigations were that lower 
energy beta emitters were more efficient in terms of self-dose to spheroids of a 
size smaller than the range of the higher energy beta emitters.  
A comparison of the dose volume histograms presented in chapter 3.4 shows 
that for the smallest 100m radius spheroid 131I is indeed the most effective 
radionuclide compared to 32P and 90Y. However, by confining the activity to the 
spheroid surface, the use of 131I becomes increasingly ineffective as the size of 
the spheroid is increased. Strikingly, this does not appear to be the case for 
either 32P or 90Y – the results presented suggest that for spheroids of diameter 
<2mm, the size of the spheroid would not affect treatment outcome (assuming 
an uptake proportional to the spheroid surface area). Although this appears 
somewhat counterintuitive, it is possible to compare the PENELOPE dosimetry 
with alternative derivations. Bardies et al used analytical expressions to 
explore absorbed dose profiles through spheroids containing either  
homogenous or surface bound activity for 22 different radionuclides [41]. When 
compared with the case of 90Y, there is no difference in the absorbed dose 
distribution at the centre of the spheroid for either 100m or 1mm radius 
spheres. Bardies et al found the absorbed dose at the surface to be 2.5 times 
greater in both instances, whilst the PENELOPE simulation predicts an 
absorbed dose 3.2 times higher. (The reasons for this are not clear although it 
can be seen from figure 3.26 that the PENELOPE derived scaled dose point-
kernel is greater than that derived analytically by Prestwich al lower values of r.) 
Moreover Bardies et al published their data in terms of S-Factors (cGy / Bq-s). 
The difference between the respective S-Factors for 100m and 1mm is 100. 
i.e. the respective difference in surface area. Thus, this would appear to 
confirm the observation made above regarding the apparent unimportance of 
the spheroid radius relative to the efficacy of treatment with high energy beta 
emitters such as 90Y.  
Although the focus of the work carried out in this chapter has been the use of 
Monte Carlo techniques to establish a link between the amount of radioactivity 
used in-vitro and the radiation absorbed by cell cultures, it is worth pointing out 
that alternative techniques have been explored. Gear et al have explored the 
potential of the type of polymer gels normally used to verify intensity modulated 
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radiotherapy [101]. They concluded that such a gel mixed with a radioactive 
source and subsequently imaged using MRI, provided a potential means of 
obtaining absorbed dose distributions in any arbitrary geometry.  Others have 
used radiochromic film to measure the dose distribution within a liquid source 
of 153Sm [102]. 
There are of course limitations to the approach taken to dosimetry in this 
chapter. Although the application of a MIRD S-factor model to a simulation of 
homogenously distributed activity works well, this approach is increasingly 
limited when applied to lower energy emissions originating from 
radiopharmaceuticals bound to a heterogeneous distribution of cells 
However, for the purposes of the experiments presented in the subsequent 
chapters, the Monte Carlo derived S-Factors relating radioactivity in 6 well 
plates to absorbed dose in cell cultures, represent a validated and accurate 
method of assessing the delivery of radiation dose.  
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4 Low Dose-Rate Irradiation Applied to Hematopoietic 
Cells  
4.1 Introduction 
The interpretation of the LQ model is that fatal damage to a cell is caused by 
either multiple single strand breaks or double strand breaks in the DNA helix 
caused directly by ionising radiation. However, in light of alternative biological 
phenomena such as hypersensitivity and the bystander effect as described in 
chapter 1.3, as well as the complexity of the response to radiation at the level 
of molecular biology, it should not necessarily be taken for granted that the LQ 
model developed for optimising fractionation regimes in EBRT can be directly 
translated to applications in TRT. In particular, it has been proposed that 
apoptosis may be a mode of cell death more likely to be associated with low 
dose-rate irradiation and that therefore models of cell survival developed to 
model responses to acute irradiation of DNA, may not be appropriate.  
Hence, the aim of the following chapter was to describe the response of 
different hematopoietic cell lines (already known to enter into apoptosis in 
response to ionising radiation) exposed to EBRT using the LQ model.  The 
model parameters were then used in conjunction with versions of the LQ model 
developed for exponentially decreasing irradiation, to make predictions of the 
response of these cell lines to an in-vitro simulation of TRT. The results of 
these predictions of clonogenic survival are compared to measured data.  
In parallel with this work the relative importance of apoptosis in TRT vs EBRT 
was also explored. Following irradiation with either EBRT or TRT, temporal 
changes in ATP levels as well as caspase 3/7 levels were measured, in order 
to investigate the hypothesis that apoptotic response is more likely following 
prolonged low dose-rate irradiation.  
 
4.1.1 Materials and Methods 
The HL60 and MOLT-4 leukaemic cell lines were grown in suspension as 
described in chapter 2.2.  After splitting the cells, 6x10ml aliquots of each cell 
culture were dispensed into 25cm2 flasks and exposed to EBRT as described 
in chapter 2.3. Each aliquot was treated with 0Gy, 0.5Gy, 1Gy, 2Gy, 5Gy and 
Low Dose-Rate Irradiation Applied to Hematopoietic Cells  
106  
10Gy respectively using the 137Cs irradiator.  Assessments of absorbed dose 
were made in-situ. After 48 hours incubation, each sample was set up for a 
clonogenic assay as outlined in chapter 2.6.1.  These experiments were 
carried out in duplicate.  
For the purposes of simulating TRT in-vitro, radioactivity concentrations of 90Y-
EDTA ranging from 110kBq/ml – 4MBq/ml were used to deliver absorbed 
doses up to 23Gy to 2.5ml aliquots of HL60 and MOLT-4 cells cultured in 6 
well plates. The S-Factors presented in table 3.2 were used in these 
calculations.  These aliquots were subsequently incubated and assayed for 
survival in an identical manner to the EBRT treated cells.  
The clonogenic cell survival curves for HL60 and MOLT-4 cells treated with 
both EBRT and TRT are presented in chapter 4.2.1.  Chapter 4.2.2 describes 
the immediate response of the cell lines following treatment in terms of 
changes in viability and levels of caspase-3/7. An extension of the LQ model 
derived by Dale is explored in chapter 4.2.3 and compared to the experimental 
data. The results are discussed in the context of current literature in chapter 
4.2.4.  
 
 
Low Dose-Rate Irradiation Applied to Hematopoietic Cells  
107  
4.2 Response to Radiation of Hematopoietic Cell 
Lines 
4.2.1 Clonogenic Survival Results 
The initial aim was to characterise the response of cells to a single non-
fractionated dose of irradiation. The clonogenic survival of both MOLT-4 and 
HL60 cells in response to a single non-fractionated dose of external radiation is 
shown in figure 4.1. Both cell lines are observed to be relatively sensitive to 
ionising radiation delivered in this manner, although MOLT-4 cells are more 
radiosensitive.  
A least squares fit was used to apply a Linear Quadratic model to both the 
HL60 and MOLT-4 survival data.  Each survival curve displayed an initial 
shoulder that then fell off with increasing dose.  MOLT-4 cells were seen to be 
more radiosensitive than the HL60 cells. The LQ parameters were  = 0.25,  
= 0.076, / = 3.2;  = 0.8,  = 0.21, / = 4; for the HL60 and MOLT-4 cells 
respectively. These parameters were used as the basis for the subsequent 
application of the radiobiological modelling of cell survival in response to TRT, 
presented in chapter 4.3. 
When the clonogenic survival of both HL60 and MOLT-4 cells, exposed to 90Y-
EDTA, is compared to their respective responses to the delivery of an acute 
dose of irradiation, marked differences are observed (See figure 4.2). 
Protracted low dose-rate irradiation was seen to be significantly less effective 
than a single acute dose of gamma radiation. At 10Gy the simulation of TRT 
was less effective than EBRT by at least three orders of magnitude for 
treatment of both HL60 and MOLT-4 cell lines. 
In contrast to the EBRT survival curves, there was no “shoulder” to the 
observed curves which are much closer to a linear behaviour. In the case of 
the HL60 cells, there is little difference in the dose-response relationship 
whether treatment is delivered over 12 hrs or at a lower dose-rate over 48 
hours.  
The response of the MOLT-4 cells, on the other hand appears to be more 
sensitive to differences in treatment time. By treating over 12 hours instead of 
48 hours (i.e. a x4 increase in dose-rate for corresponding dose-points) the  
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Figure 4.1 Clonogenic Survival in Response to Gamma Irradiation of A) HL60 and B)MOLT-4 
cell lines 
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Figure 4.2 Clonogenic Survival in Response to Irradiation with 
90
Y-EDTA of A) HL60 and 
B)MOLT-4 cell lines. (Errors too small to be visualised) 
 
B) 
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efficacy of treatment was brought closer to that of an acute single delivery of 
radiation. 
 
4.2.2 Immediate Changes in Cell Viability and Caspase-3/7 Levels 
As well as measuring response to treatment in terms of clonogenic survival, 
post irradiation changes in levels of ATP and caspase 3/7 activation were 
measured using the techniques described in chapter 2.6.2 and 2.6.3. The aim 
of these experiments was to compare the immediate biological response to 
TRT in comparison to EBRT – in particular to determine the relative role of 
apoptosis in each treatment modality. 
Figure 4.3 compares the response of HL60 cells to either EBRT or TRT. In the 
case of the EBRT treatment there was an immediate loss of viability following a 
10Gy absorbed dose of gamma irradiation. At the lower 5Gy absorbed dose 
there was neither a decrease nor increase in viability immediately post 
irradiation. Instead a decrease of ATP was not seen until 48 hours following 
treatment. A similar delayed reaction was observed after initiation of treatment 
with 90Y-EDTA for the TRT treated cells at all doses of 90Y-EDTA, although the 
relative loss of cell viability after 96 hours was seen to be dose-dependent. 
Post treatment, no immediate change in caspase-3/7 levels are observed with 
the exception of the 10Gy EBRT HL60 cells. A delay of 24 hours was seen 
before cells exposed to lower doses of EBRT exhibited an increase in 
caspase-3/7 levels. In the case of TRT treated HL60 cells this delay was 
increased to 48 hours. The rise in caspase 3/7 levels would appear to precede 
the subsequent drops in cell viability. Hence it seems reasonable to conclude 
that apoptosis is a significant mode of cell death for HL60 cells treated with 
either TRT or EBRT.  
However, for both treatment modalities, the magnitude of the change in 
caspase-3/7 levels does not appear to be directly proportional to the absorbed 
dose. As well as presenting caspase-3/7 levels as a function of time, it is also 
possible to present the cumulative apoptotic response by integrating the 
caspase-3/7 levels over time (see figure 4.3). Again it was seen that although 
there is an initial increase in the apoptotic response as the absorbed dose 
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increases, it was then observed to asymptote. This was the case for both 
EBRT and TRT. 
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Figure 4.3 Change in levels of ATP and Caspase 3/7  post treatment of HL60 cells by EBRT and 
TRT. 
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The equivalent set of results for the MOLT-4 cells are shown in figure 4.4. It 
can be seen that EBRT elicits an immediate change in the number of viable 
cells regardless of the absorbed dose. The decrease is dose-dependent, 
although after 80 hours the beginning of a recovery regrowth phase is 
observed in the 2Gy sample. For TRT the higher concentrations of 90Y-EDTA 
resulted in an immediate loss of viable cells. As the radioactivity concentration 
was lowered a slower response was seen. For the lower concentrations of 
radioactivity, the rate of cell proliferation is initially matched to that of the 
negative control cells. As the accumulation of absorbed dose causes the rate 
of cell death to outweigh proliferation, this is reflected as a loss of viability.  In 
comparison to the HL60 cell responses, the increased radiosensitivity of the 
MOLT-4 cells was apparent. Despite their greater radiosensitivity and the 
larger loss of cell viability, the caspase-3/7 level responses of the MOLT-4 cells 
are not significantly higher than those displayed by HL60 cells.  
In the case of the external beam treatment, at 24 hours post irradiation the 
caspase 3/7 levels demonstrated clear dose dependence, although the 
increase in caspase 3/7 activation per unit absorbed dose decreases as the 
absorbed dose rises towards 10Gy. The same is true of the cells treated with 
90Y-EDTA. 
Beyond 24 hours the level of caspase-3/7 in cells exposed to lower radiation 
doses continued to rise, whereas for MOLT-4 cells exposed to higher doses, 
caspase-3/7 levels either remained stable or began to decrease. The net effect 
was that, particularly for MOLT-4 cells exposed to TRT, the cumulative total of 
caspase-3/7 activation again asymptotes beyond a certain dose.  
Overall, these results would suggest that there is a limit on the role played by 
apoptosis and that at higher doses in particular, an alternative mode of cell 
death must be responsible for the significant decreases in clonogenic survival 
observed.  
Although for both HL60 and MOLT-4, there are temporal differences in the 
response to irradiation between EBRT and TRT, the magnitude of caspase 3/7 
activation relative to a negative control cell population is not significantly 
different between modalities. Hence it is not possible to conclude that for cells 
Low Dose-Rate Irradiation Applied to Hematopoietic Cells  
113  
with the potential to undergo apoptosis in response to radiation, a low dose-
rate treatment modality is of particular advantage.  
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Figure 4.4 Change in levels of ATP and Caspase 3/7 post treatment of MOLT-4 cells by EBRT and 
TRT. 
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4.2.3 Bystander Effect Media Transfer  
Media from irradiated HL60 and MOLT-4 cell cultures was transferred to 
recipient cell cultures which were then incubated for a further 48 hours. 
However clonogenic assays of these recipient cells showed no difference in 
cell survival to negative control samples. i.e. no bystander effect was 
demonstrated for these cell lines.  
 
4.2.4 Applying the Linear Quadratic Model to TRT 
In chapter 1.3.8 the concept of the Linear Quadratic model was used to explain 
fractionation effects. In order to compare the relative effect of different 
fractionation schemes the concept of the Biologically Effective Dose (BED) was 
introduced [102]. By definition this is given by, 
 
 

S
BED
ln  
 
Equation 4.1 
 
The BED can also be expressed conceptually as, 
 
BED = Total Dose x Relative Effectiveness  
Equation 4.2 
 
For the case of fractionated EBRT delivery, it can be derived from equations 
4.1 and 1.7 that, 




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Equation 4.3 
 
Hence the relative effectiveness is given by (1+d(/)). In this case it is simple 
to observe that increasing the dose per fraction will increase the relative 
effectiveness of a fractionation schedule.  
Expressions for BED have also been developed by Dale for both the case of a 
continuously irradiating low dose-rate (CLDR) delivery as well as for a 
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monoexponentially decaying radiation (MDR) delivery [104, 105]. As well as 
calculating doses based upon the combination of (initial) dose-rate and 
treatment times, these models also introduce parameters that account for the 
repair of tissue over the course of radiation delivery and the time over which 
treatment is delivered.  
 
Continuous Low Dose-Rate Irradiation, 
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Equation 4.4 
 
R=Dose-rate; T = Treatment Time; 
 = Sub-lethal repair constant = 
 
rt
2ln
 
where tr is an expression of the repair time. 
 
For a monoexponential dose-rate, 
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Equation 4.5 
 
 
 
For the MDR model described above it is assumed that the radiation source is 
allowed to decay until infinity. For occasions when the treatment delivery is 
limited to a finite period of time, T, then RE is given thus [103].  
 
R0 =Initial Dose-rate =Decay constant   = Sub-lethal repair constant 
Low Dose-Rate Irradiation Applied to Hematopoietic Cells  
116  
 
 
T
T
T
eC
e
B
e
A
where
C
BAR
RE
























1
1
2
1
2
1
(
2
0
 
Equation 4.6 
 
Thus, equations 4.1, 4.2 and 4.5 may be used to predict the response to TRT 
using the  and  parameters derived from the results of EBRT experiments. 
The only unknown parameter is the sub-lethal repair constant, . The 
significance of the repair constant, on the predicted survival of both MOLT-4 
and HL60 cells is shown in figures 4.5 and 4.6 respectively. For both cell lines, 
varying the repair constant causes the predicted survival to vary, between the 
linear quadratic survival observed in response to a single fraction of EBRT and 
a linear survival curve (normally described as a continuous repair model). As 
the ratio of repair time to treatment time is decreased, the predicted survival 
tends increasingly towards the latter. 
For the MOLT-4 cells a repair time of 1 hour looks to be the most appropriate, 
showing good agreement with both sets of measured data, whilst for HL60 a 
repair time of 30 minutes may be more appropriate.  
However, for the treatments used in clinical practice, the treatment time is 
typically to infinity and thus the precise magnitude of a repair factor becomes 
less important, so long as it can be assumed to be small relative to the 
treatment time. Both the experimental data observed, and the LQ formalism of 
Dale applied to the data, suggest that if the dose-rate is decreased and 
equivalent doses are delivered over longer periods of time, then the continuous 
repair model may be a reasonable approximation of the cell survival that could 
be anticipated.  
One of the limitations of the experimental data presented is the restriction of 
the treatment time to 48 hours. However, as the analysis of caspase 3/7 
activation showed, the cell cultures left unattended would pass into apoptosis 
spontaneously (due to a lack of media change and/or splitting of cell cultures). 
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As a result, it would have been problematic to have a negative control against 
which to compare treated aliquots of cells. 
Further limitations – could have used the same cell line with and without 
functional p53 
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Figure 4.5  Modelling the Response of MOLT-4 cells treated with 
90
Y-EDTA over A) 12 hours and 
B) 48 hours 
 
A) 
B) 
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Figure 4.6  Modelling the Response of HL60 cells treated with 90Y-EDTA over A) 12 hours and B) 
48 hours 
 
A) 
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When discussing the application of the LQ model to prolonged treatments with 
ionising radiation, the BED has been further modified by the introduction of a 
repopulation factor, designed to account for the proliferation of cells during the 
course of treatment. Thus,   
 
BED = Total Dose x Relative Effectiveness – Repopulation Factor 
Equation 4.7 
 
 
avT
T
RF

693.0
  
Equation 4.8 
 
Tav is the average doubling time of the cell population.  
 
However, this repopulation factor has not been taken into account for the 
analysis of the experimental results presented. The clonogenic survival data 
shown is measured relative to a negative control in each case, thus accounting 
for inherent cell proliferation over the respective treatment times.  
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4.3 Discussion 
There is a clear difference in the effectiveness of TRT in comparison to single 
fraction EBRT (See figure 4.2). The range of doses covered matches those 
measured clinically in trials of 90Y-Zevalin [183].   At low doses the difference is 
relatively small, but at higher absorbed doses TRT treated cells cease to 
display the “shoulder” associated with the quadratic term of the LQ model and 
are closer to a linear change in cell survival. However, despite this difference, it 
has been shown that modified versions of the LQ model can be used to predict 
the clonogenic survival of both HL60 and MOLT-4 cells exposed to TRT, using 
parameters derived from EBRT survival data.  
A number of direct comparisons of radiosensitivity to TRT in comparison with 
EBRT have been made. Certain early investigations of the efficacy of 
radioimmunotherapy (RIT) in preclinical animal models suggested that RIT was 
more effective than EBRT. However, a review of these studies by Knox  [106] 
demonstrated a wide variation in the findings of such studies, such that RIT 
was found to be “more effective, less effective, or as effective as equivalent 
doses of external beam XRT.” This somewhat broad finding even extended to 
investigations of xenografts of the same colorectal cell line (as carried out by 
different authors).  
With regards to the cell lines studied in this chapter, a linear survival curve for 
both HL60 and MOLT-4 exposed to low dose-rate gamma irradiation was 
previously reported by Vavrova et al [107]. In the case of the HL60 cells, a 
similar difference in radiosensitivity was observed between EBRT and low 
dose-rate therapy (1.8mGy/min). However, they found no difference in 
sensitivity between EBRT and low dose-rate therapy for MOLT-4.  The reason 
for the discrepancy between these results and those presented in this chapter 
is not clear, although differences in methodology regarding the irradiation of 
cells are noted. (Vavrova et al carried out low dose-rate irradiations under non-
incubated conditions, presumably for up to 24 hours, using an attenuated 
Cobalt-60 beam. Thermoluminescent devices (TLDs) were used for dosimetry.) 
A similar study of CA20948 rat pancreatic tumour cells, either incubated with 
131I or exposed to single fraction EBRT, also demonstrated the greater efficacy 
of EBRT. The survival of cells exposed to 131I appeared to follow that of the 
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shoulder of the curve observed in response to EBRT [108]. Nonetheless, 
Zhuang et al have suggested that in the case of CL187 colonic cancer cell 
lines, the use of I-125 seeds to deliver low dose-rate irradiation is more 
effective than external beam treatment delivering equivalent doses [109].  
According to the LQ model, the / ratio is a quantitative indication of the 
sensitivity of cells to a change in fractionation or dose-rate. The lower this 
value, the greater the difference between the response to acute irradiation and 
low dose-rate treatment. Values for HL60 and MOLT-4 were found to be 3.3Gy 
and 3.8Gy respectively. Therefore, it could be expected that the sensitivity of 
each cell line to TRT relative to EBRT would be similar. This hypothesis is 
based upon the mechanistic concepts behind the LQ model and does not 
account for differing molecular biological pathways in response to irradiation. 
One of the principal reasons for comparing the response of HL60 and MOLT-4 
cells was their known differences regarding the biological response to 
irradiation. In particular HL60 cells are p53 deficient, whilst MOLT-4 are p53 
wild.  
When comparing the reaction of HL60 cells and MOLT-4 cells to gamma 
irradiation, one immediately apparent difference in the subsequent viability of 
the cells is the delayed response of the HL60 line. (See figures 4.3 and 4.4) 
This delay in both initiation of apoptosis and subsequent loss of viability is most 
likely to be related to a well known G2/M cell cycle delay that is induced by 
exposure to radiation [110, 111]. Furthermore the same groups have 
demonstrated that G2/M cell cycle arrest also occurred when low dose-rate 
exposures were made using exponentially decaying radionuclides. This is in 
agreement with the findings presented in chapter 4.2.2. The delayed caspase-
3/7 activation and subsequent loss of HL60 cell viability is a phenomenon 
common to both the EBRT treatment model as well as the 90Y-EDTA TRT 
model.   
Apoptosis has been put forward as the principal mode of cell death in TRT [27, 
57]. However, the data presented in figures 4.3 and 4.4 do not necessarily 
support this hypothesis. An increased level of caspase 3/7 activation following 
irradiation is seen in both HL60 and MOLT-4 cells for both different methods of 
irradiation. In the case of gamma irradiated cells there appears to be an 
Low Dose-Rate Irradiation Applied to Hematopoietic Cells  
123  
association between the level of caspase 3/7 observed and the absorbed dose 
up to 2Gy and 5Gy for MOLT-4 and HL60 cells respectively. Beyond these 
absorbed doses the total level of caspase-3/7 detected appears to reach a limit, 
although the absorbed dose does influence the speed with which the changes 
occurred post irradiation. Thus, these results confirm what is already known  -  
apoptosis is not the only mode of cell death in high dose-rate irradiated HL60 
or MOLT-4 cell lines [112, 113]. In particular necrotic cell death is increasingly 
prevalent at high doses of ionising radiation.  
In the case of TRT, Friesen et al used Flow Cytometry to analyse the 
percentage of apoptotic cells post irradiation of HL60 cells as well as CEM 
cells [58]. Although, they also observed temporal differences in changes in 
activation of apoptosis between beta and gamma irradiated cell lines, the 
authors “found higher apoptosis rates and earlier activation of apoptosis 
pathways after gamma-irradiation”. One disadvantage of the Flow Cytometry 
technique applied is that it analysed the population of viable cells and thus 
does not account for necrotic cell death. The advantage of the caspase 3/7 
luminescence technique used in this chapter is that it allowed the investigation 
of relative levels of apoptosis across all absorbed dose points. 
Although the levels of caspase-3/7 observed initially were dependent on the 
radioactivity concentration, they did not rise to levels above those observed for 
gamma irradiated cells. Moreover, the relatively small differences in the levels 
of caspase-3/7 observed at increasing doses of low dose-rate irradiation do not 
account for the order of magnitude differences in clonogenic survival seen at 
successive absorbed dose points. Thus, it may be that as with EBRT there is a 
transition from apoptotic cell death to necrotic cell death as the dose-rate is 
increased.  
As stated previously, a significant difference between HL60 and MOLT-4 cells 
is the mutation of the p53 gene in HL60.  The presence of p53 has been linked 
to decreased radioresistance and is reflected in the greater radiosensitivity 
shown by the MOLT-4 cells. Although both cell lines displayed an apoptotic 
response to irradiation, as demonstrated both in this chapter as well as by 
others [114], the presence or absence of p53 does not appear to affect the 
sensitivity of either cell line to TRT relative to EBRT. i.e. regardless of the 
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differing biological pathways in the cell lines the LQ model is consistent in 
being able to predict the response to TRT. Nonetheless, improvements to 
experimental design regarding the effect of p53 status could be made. For 
example, it is possible to transfect cells such as HL60 so as to restore the p53 
gene. A side by side comparison of p53 null HL60 vs transfected p53 wild-type 
HL60 would allow stronger conclusions to be drawn regarding the relevance of 
p53 status to the LQ model.   
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5 Application of the LQ model to a Hypersensitive Cell 
Model 
5.1 Introduction and hypothesis 
Chapter 1.3.6 introduced the concept of hypersensitivity and the possibility of 
low dose-rate effects eliciting greater cell damage than might be expected. The 
aim of this chapter was to characterise the response to low dose-rate 
irradiation of a cell line already reported to have a hypersensitive response to 
acute radiation absorbed doses.  
The hypothesis tested was that the response of such a cell line to low dose-
rate irradiation would not be adequately modelled by the extensions of the 
Linear Quadratic Model discussed in the previous chapter, and that 
furthermore the cells would display an inverse dose-rate effect. A further aim, 
in the event of an inverse dose-rate effect being observed, was to identify any 
threshold dose-rate above or below which the sensitivity to radiation underwent 
significant change. Furthermore, a biological explanation for any low dose-rate 
effects was explored at the level of molecular biology.  
The selected cell line was PC-3, a cell line derived from human prostate 
adenocarcinoma. In chapter 5.2, the response of the cell line to acute 
irradiation and the characterisation of the survival curve are presented. 
Chapter 5.3 describes the results of exposing PC-3 cells to low dose-rate 
irradiation with 90Y-EDTA over a range of treatment times and dose-rates. 
Chapter 5.4 contains an application of the Linear-Quadratic model to the data 
presented in chapter 5.3, and introduces a suggested modification of the LQ 
model that could be applied to hypersensitive cells.  
The biological basis for the inverse dose-rate effect is explored in chapter 5.5. 
In particular the molecular pathways suggested as being the cause of 
hypersensitivity to acute irradiation are investigated following treatment with 
low dose-rate irradiation. All results are discussed in the context of existing 
literature in chapter 5.6. 
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5.2 Response of PC-3 to Acute Irradiation 
 
Adherent PC-3 cells were grown as described in chapter 2.1. For delivery of 
acute irradiation, the 137Cs Irradiator was used (chapter 2.2). Cell survival was 
assessed with a clonogenic assay using Crystal Violet staining (chapter 2.3.) 
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Figure 5.1 Response of prostate adenocarcinoma PC-3 cells to acute gamma radiation 
 
 
The cell survival curve for PC-3 in response to acute irradiation is shown in 
figure 5.1. As previously, the data was modelled to a linear quadratic function 
using a least squares fit. The model parameters were  = 0.085Gy-1 ± 0.04 and 
 = 0.093Gy-2 ±0.004.  
The curve has the low alpha/beta ratio and broad shoulder associated with late 
responding normal tissues, before falling off quickly at doses beyond 2Gy. 
Although the error bars are reasonably small it is not possible to objectively 
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perceive any hypersensitivity at low absorbed doses. This would be shown by 
survival at low absorbed doses falling beneath the level described by a linear 
quadratic description of cell survival, before returning to “normal” linear 
quadratic behaviour at higher absorbed doses.  
This type of response to ionising radiation has previously been modelled by an 
adapted version of the Linear Quadratic model termed the induced repair (IR) 
model [115]. 
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Equation 5.1 Induced Repair Model of Cell Survival 
 
In this model s is the slope of the survival curve observed during the 
hypersensitive phase, whilst Dc represents a threshold absorbed dose above 
which these effects no longer apply. An example of the model is provided for 
illustration in figure 5.2a in which s/ equals 30 and Dc is set to 1Gy. For the 
purposes of the illustration the values for  and  derived from the PC-3 
survival curve are used. The result is a clear difference in the nature of the 
survival curves. However, according to Joiner et al thes/  ratio for PC-3 is 
approximately 6.5 [60]. If this value is used in the IR model, figure 5.4b is 
obtained and it becomes apparent why such an effect cannot be observed in 
the data presented. At this lowers/  ratio the effect is much more subtle and 
it is clear that the clonogenic assay used lacks the precision to allow the 
characterisation of such small deviations from a standard model.  
The measured survival curve compares well with other published data on the 
response PC-3 cells to irradiation [62, 116, 117]. The / ratio of ~0.9Gy is 
much lower than most tumour types which are typically higher than 4Gy. 
However this compares reasonably well with clinical estimations of an / ratio 
equal to ~1.5Gy in prostate carcinoma [118].  
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Figure 5.2 The effect of hypersensitivity on cells with a) a hypothetical s/ ratio of 30 and b)  an 
s/ ratio of 6.5 as measured for PC-3 cell line [60]. 
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5.3 Response of PC-3 to Low Dose-Rate Exposure  
In the case of hypersensitive cell lines, the linear quadratic model does not 
predict the response to radiation at low absorbed doses. Therefore it is likely 
that such cell lines would fail to conform to the linear quadratic model, when 
exposed to low dose-rate irradiation.   
PC-3 cells were cultured in 6 well plates and incubated with 90Y-EDTA in order 
to provide low dose-rate irradiation. Cells were treated at dose-rates ranging 
from 0.06Gy/hr to 1.1Gy/hr. Cells were treated for either 24, 48, 72 or 96 hours. 
For each timepoint, an unirradiated negative control aliquot of cells was also 
incubated. Response was measured using the clonogenic assay.  
The results of this experiment are shown in figure 5.3 alongside the response 
of the cells to an acute absorbed dose of external beam radiation. The data 
points are grouped according to treatment time.  
Initially, between 0-0.5Gy, the survival curves follow the shoulder of the acute 
exposure curve. Beyond 0.5-12Gy, it is possible to differentiate between the 
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Figure 5.3 Response of PC-3 cells to low dose-rate 
90
Y-EDTA irradiation over 24, 48, 72 or 96 
hours. Responses are shown in relation to the response of PC-3 cells to acute irradiation. 
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groups. The longer the treatment time (and therefore the lower the dose-rate 
for a given absorbed dose), the more effective the treatment.  This inverse 
dose- rate effect is a notable departure from what might be expected from a 
classical dose-rate relationship. However, even the most effective treatment 
regime (T=96 hours) is not as effective as the acute single fraction dose 
delivery used to define the radiosensitivity of the cell line.  
The data presented in figure 5.3 is grouped by common treatment times T. 
Therefore the higher absorbed dose points are equivalent to higher dose-rates. 
Beyond 12Gy, for those cells treated over 96 hours, there would appear to be a 
change in the slope of the survival curve, indicating decreased radiosensitivity 
per unit dose. Such a transition in the slope of the survival curves is also seen 
for cells treated over shorter periods of time, albeit at lower absorbed doses as 
the treatment time is reduced.  
Although, the results clearly demonstrate an inverse dose-rate effect, it would 
appear that as the total radiation absorbed dose delivered increased beyond 
20Gy, then a treatment time of 24 hours (higher dose-rate) is more effective 
than the equivalent absorbed dose delivered over 48 hours and 96 hours. 
From these observations, it seems likely that cells are more sensitive to 
ionising radiation delivered below a threshold dose-rate. Above this dose-rate, 
radioresistance of the cells initially increases. However, as the dose-rate is 
then further raised, radioresistance decreases. In the next section, the Linear 
Quadratic model and the concepts of Biologically Effective Dose, are applied to 
this hypothesis. 
According to the classical theory of radiation damage as either double or single 
strand breaks occur in DNA, a higher dose-rate should lead to additional single 
strand breaks in sections of DNA, already subjected to single strand breaks 
which have not had the time to repair, and consequently result in fatal damage 
to the cell. In the case of the data presented this is not so – although the acute 
irradiation is still the most damaging, the 96 hour treatment regime (lower 
dose-rate) is apparently more effective than the 24 hour treatment (higher 
dose-rate) and up to 5Gy is equally as effective as a single acute dose.  
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5.4 Application of the LQ Model to Inverse Dose-
Rate Effect 
 
In chapter 4, it was demonstrated how characterising the alpha and beta 
parameters of a given cell line made it possible to predict the response of that 
cell line to protracted low dose-rate irradiation by using the following equations.  
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Equation 5.2 LQ Model Applied to Low Dose-Rate Irradiation 
 
SF = survival; BED = Biologically Effective Dose; D = total absorbed Dose; RE 
= Relative Effectiveness; R0 = Initial Dose-Rate;  = the exponential decay 
constant; and  is the repair constant. 
 
Using the values for α and β, determined in chapter 5.2 (0.085 and 0.093 
respectively), the same equations were used to model the response of PC-3 
cells irradiated for 24 hours. As previously, a least squares fit of the 
experimental data to the adapted LQ model was used to find an appropriate 
value for the repair parameter µ. The results of the fit are shown in figure 5.4, 
alongside the clonogenic survival predicted by alternative values of µ. As 
shown previously, the value chosen for  has a significant effect on the degree 
of cell killing predicted.  A value of 0.73hr-1 (equivalent to a half repair time of 
0.95 hours) was chosen for further modelling of the response of the PC3 cells 
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Figure 5.4 Effect of assumed repair time on modelling the response of PC-3 cells to low dose-rate 
irradiation 
 
If the value of =0.73 is used to predict survival to low dose-rate irradiation 
delivered over 48 and 96 hours, then the curves predict an increase in cell 
survival as the dose-rate at which a particular absorbed dose is reached 
decreases (see figure 5.5). However, when compared to the experimental data 
it can be seen that such a model clearly does not account for the behaviour 
observed. For each treatment time, the experimental data appeared to 
“undercut” the expected behaviour at lower absorbed doses before reverting 
towards the survival predicted by the model at higher absorbed doses. The 
difference between the predicted and the measured survival becomes 
increasingly large as the treatment time is increased. This data would therefore 
appear to support the hypothesis that below a critical dose-rate, PC3 cells are 
more sensitive to radiation. As the dose-rate rises above the threshold, the 
cells cease to behave in this hypersensitive manner and cell survival reverts to 
behaviour in keeping with the LQ model.  
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Figure 5.5 Comparison of LQ Model Predictions vs Experimental Data. A value of =0.73hr-1 is 
assumed for all modelling. 
 
 
In order to explore this further, the concept of the Biologically Effective Dose 
(BED) was used to compare the different treatment regimes. The measured 
BEDs were compared with those predicted by the LQ model. (See figures 5.6a-
d.) As the treatment time is increased, the discrepancy between the predicted 
BED and the measured BED becomes increasingly large. The longer the 
treatment time, the higher the absorbed dose at which the discrepancy is 
resolved.  If the ratio of the measured BED to the predicted BED is plotted as a 
function of the initial dose-rate, rather than absorbed dose, then an interesting 
finding is observed (see figure 5.7). Although, the magnitude of the increased 
sensitivity to radiation is a function of the treatment time, there appears to be a 
common dose-rate (~0.5Gy/hr) beyond which there is no increased sensitivity 
to radiation. 
According to the data presented, no increase in biologically effective dose 
occurs beyond a threshold dose-rate of 0.5Gy/hr. Such an increase is most 
apparent for cells treated over longer periods of time. It would also appear that 
Application of the LQ model to a Hypersensitive Cell Model 
134  
such an increased sensitivity to radiation does not occur at the very lowest 
dose-rates.  
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Figure 5.6: Comparison of predicted vs measured  Biologically Effective Dose for 
90
Y-EDTA 
treatment of PC3 cells over a) 24 hours; b) 48 hours; c) 72 hours. d) 96 hours. 
 
 
a) b) 
c) d) 
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Figure 5.7 Ratio of actual BED to BED predicted by LQ model as a function of the inital dose-rate 
 
 
In the case of the Induced Repair Model (equation 5.1), used to describe 
hypersensitivity in response to low single fraction doses of radiation, the αD 
term of the Linear Quadratic equation is modified to reflect the higher 
radiosensitivity displayed at low absorbed doses. A higher radiosensitivity 
could be due to a number of reasons – a higher than expected degree of 
physical damage; a greater propensity for cell death, due to changes in the 
activation of particular cell death pathways; or a change in the effectiveness 
with which damage is detected and repaired. 
Since the physical nature of the ionising radiation is no different at low dose-
rate, the first possibility of increased physical damage seems improbable. From 
the data presented, it would appear that all survival data falls somewhere in the 
region bound by the response to acute irradiation, and the continuous repair 
model defined by exp(-αD), and that at no point is the delivery of low dose-rate 
irradiation more effective than single fraction dose delivery. Therefore a 
change in the efficiency of the repair process may be the most likely cause for 
the inverse dose-rate effect.  
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If this were the case, then the Dale version of the LQ model could still be used 
as the basis for modelling response to low dose-rate irradiation. Under normal 
circumstances, the parameter  is a constant used to describe a time-
dependent repair process. In a hypothetical version of the model, which aims 
to describe the apparent biological outcomes presented above, it could instead 
be redesignated as a function of the initial Dose-rate, D0. In the example 
shown below, the repair parameter is presented as a dose-rate dependent 
sigmoid function, describing a transition from no repair at low dose-rates to 
“normal” repair beyond 0.5Gy/hr. 
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Figure 5.8 Threshold model of repair factor  
 
The curve is described by the following equation:  
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Equation 5.3 Dose-Rate dependent repair process 
 
Dc is the critical dose-rate at which  has reached 50% of its maximum value, 
whilst m is a parameter which controls the rate of change of the sigmoid 
function. 
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Figure 5.9 The Effect of a dose-rate dependent value of  on the LQ model. A)  as a function of 
dose-rate. B) Corresponding Survival Curves. (=0.085,  = 0.093, T = 96 hours.) 
 
The result of this adaptation of the model is to describe a survival curve that 
initially follows the curve seen in response to acute single fraction irradiation, 
but then makes a transition to a survival curve in which the repair process is 
hampering cell kill. Figure 5.9 shows the sensitivity of the model to the shape 
of the sigmoid curve used to describe ., It can be seen that parameters may 
be selected which result in a good fit of this adapted LQ model to the 96hr 
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experimental data (T=96 hours). However, the same parameters (m=20, 
Dc=0.5Gy/hr) do not result in such a good fit for the 48 and 72 hour exposures 
(see figure 5.10.) 
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Figure 5.10 Adapted LQ model applied to experimental data. 
 
There are a number of limitations of this model which may explain this. Firstly, 
as with any version of the Linear Quadratic model, it is based upon a 
simplification of the biological response that may or may not be appropriate. 
Secondly, the extension of the model described in this chapter is based on the 
hypothesis that the repair process is a function of the initial dose-rate D0. The 
main reason for making this assumption was mathematical, rather than 
biological – in this way  is not a function of time and thus the solution to the 
LQ model still holds true. (See appendix 2.) It may be that a model in which  
is a function of the dose-rate at time t would be a more appropriate form of the 
LQ model. Unfortunately it was not possible to derive an analytical solution to 
such a model. However, it was instead possible to make  a function of the 
average dose-rate rather than the initial dose-rate. Since the average dose-
rate of an exponentially decaying source is related to the treatment time T, this 
results in a better correlation between the experimental data and the proposed 
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model (see figure 5.11). In particular, the increase in BED relative to that 
predicted by the standard LQ model is now reduced with treatment time. 
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Figure 5.11 Further Adaptation of the LQ model applied to experimental data. In this case,  is a 
function of the average dose-rate, rather than the initial dose-rate. (m=18, Dc=0.31Gy/hr) 
 
An alternative to the proposed models, would be one in which the parameters 
defining radiosensitivity,  and , were made a function of dose-rate instead of 
. This would have the advantage of not constraining the effectiveness of low 
dose-rate irradiation to no more than that observed in response to acute single 
fraction irradiation. However, consideration of equation 5.2 shows that any 
such model would not result in a relative effectiveness that was also time 
dependent.  
If estimations of cell survival are made based upon these extensions of the LQ 
model then some interesting effects are predicted. Figure 5.12a shows the 
predictions of cell survival for hypothetical treatments at different dose-rates 
based upon the version of the model in which  is a function of initial dose-rate. 
For each curve shown there is a fundamental limit on the maximum absorbed 
dose achievable. This is due to the relatively short half-life of the 90Y. E.g. If the 
initial dose-rate is 0.25Gy/hr and this follows a monoexponential decay with a 
half-life of 2.67 days then at T=∞ the absorbed dose delivered is 27.5Gy. If the 
initial dose-rate is doubled to 0.5Gy/hr then the maximum absorbed dose 
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delivered is also doubled. However, it is striking to note that due to the inverse 
dose-rate effect the cell kill is higher at the lower applied dose-rate, even 
though the total absorbed dose absorbed is lower by a factor of 2. 
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Figure 5.12 Predictions of cell survival in response to 
90
Y delivered at varying initial dose-rates. A) 
 is a sigmoid function of initial dose-rate. B)  is a sigmoid function of the average dose-rate 
Actual experimental data points are also shown. 
 
A) 
B) 
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The experimental data are in fact, better fitted by the alternative proposal, in 
which  is a function of the average dose-rate (see figure 5.12b). Similar 
qualitative trends are predicted. Nonetheless, at high absorbed doses this 
model should be treated with caution.  was made a function of average dose-
rate to provide an approximate solution to an integration that could otherwise 
not be solved. As T approaches infinity, this approximation is increasingly less 
appropriate, since for any dose-rate, the average will approach zero and thus, 
the predicted cell kill will be equivalent to that resulting from an acute exposure 
to radiation. 
 
 
.   
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5.5 Biological Investigation of Inverse Dose Rate 
Effect 
 
 
 
 
Figure 5.13 Illustration of cell signalling pathways related to G2/M cell cycle arrest (taken from 
http://www.cellsignal.com/reference/pathway/Cell_Cycle_G2M_DNA.html, 19/07/11) 
 
 
In chapter 5.4, a threshold dose-rate of 0.3-0.5Gy/hr was identified (see figure 
5.7). Below this dose-rate, PC-3 cells appeared to be more sensitive to ionising 
radiation than predicted by the Linear Quadratic model. The aim of this section 
was to explore the cellular response to irradiation in terms of molecular biology. 
In particular, pathways already associated in the literature with hypersensitivity 
to acute radiation exposure, were investigated in order to identify any 
molecular link between hypersensitivity and the inverse dose rate effect.  
Figure 5.13 illustrates some of the common signalling pathways which can 
occur following exposure to ionising radiation and ultimately lead to cell cycle 
arrest at the G2/M checkpoint. This checkpoint has been cited as one of the 
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principal explanations for hypersensitivity in response to single fraction 
irradiation [115]. In particular, the ATM and Chk2 pathways were selected for 
investigation using Western Blot techniques to identify levels of these proteins 
post irradiation. The hypothesis behind these experiments was that G2/M cell 
cycle arrest would only occur above a threshold dose-rate. 
Cells were aliquoted into 6 well plates as previously and treated with 
concentrations of 90Y-EDTA, such as to cause initial dose-rates of 0.05Gy/hr; 
0.1Gy/hr; 0.2Gy/hr; 0.3Gy/hr and 0.5Gy/hr as well as a negative control 
population. Several such well plates were set up, to allow harvesting of cells at 
more than one time point. Cells were lysed and probed for specific proteins as 
described in chapter 2.3.4. As well as measuring the phosphorylated form of 
Chk2 (Ck2-p), antibodies for ATM and ATM phosphorylated at serine 1981 
were also used. In addition cleaved PARP, a marker for apoptosis, was also 
probed for. For the purposes of comparison with a cell line already shown to 
lack an inverse dose-rate effect and known to readily go into G2-M arrest, 
HL60 cells were also treated and probed for Chk2-p. All blots were also probed 
for tubulin, to account for differences in total protein levels between samples. 
In addition to using Western Blot techniques to probe for specific proteins, the 
Cell TiterGlo assay was applied to PC-3 cells treated with 90Y-EDTA in normal 
cell culture media. The cells were incubated in 96 well plates at dose-rates of 
0.05, 0.1, 0.2, 0.3, 0.5 and 0.8Gy/hr. The aim of this was to measure the 
effects of dose-rate upon cell proliferation and cell death during irradiation. 
Measurements were made every 48 hours, until the negative control cells 
reached confluence and ceased to proliferate. 
The results of the Western Blot investigations are summarised in tables 5.1 to 
5.4. When HL60 cells were exposed to low dose-rate irradiation, then higher 
levels of phosphorylated chk2 protein were observed in response, indicating 
the activation of a G2-M cell cycle arrest as part of the overall response to 
irradiation. It would appear that the level of protein phosphorylation is 
approximately proportional to the applied dose-rate. A different type of 
relationship might be expected for a cell line that displays increased sensitivity 
to low dose-rate irradiation. i.e. in the case of PC-3 cells, one can hypothesise 
that phosphorylation of Chk2 is absent at dose-rates below a threshold dose-
rate, such as that identified in chapter 5.4.  
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Initially this would appear to be the case (see table 5.2). At 3 hours post 
irradiation, no increase in Chk2 phosphorylation was seen at dose-rates less 
than 0.2Gy/hr. However, at 24 hours and beyond, Chk2 phosphorylation is 
seen in response to all dose-rates. i.e. although there would appear to be a 
threshold absorbed dose (~ 1Gy) below which cell cycle arrest at G2-M does 
not occur, there is no threshold dose-rate required for the activation of this 
pathway. It is also worth noting that, once activated, Chk2-p levels appear 
constant over time at least up to 72 hours. 
 
 Initial Dose-Rate (Gy/hr) 
 0.5 0.3 0.2 0.1 0.05 0 
T=5 hrs 
 
 
T=48 hrs 
Table 5.1 Phosphorylated Chk2 Protein Levels in Irradiated HL60 Cells 
 
 Initial Dose-Rate (Gy/hr) 
 0.5 0.3 0.2 0.1 0.05 0 
T=3 hrs 
 
T=24 hrs 
T=72 hrs 
Table 5.2 Phosphorylated Chk2 Protein Levels in Irradiated PC-3 Cells 
 
 
 Initial Dose-Rate (Gy/hr) 
 0.5 0.3 0.2 0.1 0.05 0 
ATM (T=24 hrs) 
 
Tubulin (T=24 
hrs) 
Table 5.3 ATM Protein Levels in irradiated PC-3 cells alongside Tubulin control levels 
 
Application of the LQ model to a Hypersensitive Cell Model 
145  
Chk2 is phosphorylated downstream of ATM. As table 5.3 illustrates, ATM is 
present in PC-3 cells. However, total levels of ATM do not change in response 
to radiation. Instead, ATM autophosphorylates in response to DNA damage 
[119]. Unfortunately, probing for the phosphorylated version of ATM did not 
result in detection of an observable signal. 
Analysis of the changes in ATP levels following irradiation provide further 
support for an inverse dose-rate effect (see figure 5.14). At 48 hours, cell 
proliferation in PC-3 cells irradiated at dose-rates below 0.5Gy/hr appears to 
be significantly reduced relative to negative control samples as well as cells 
irradiated at 0.5Gy/hr and 0.8Gy/hr (p=0.039). At 96 hours and beyond, the 
proliferation of the cells irradiated at these higher dose-rates is arrested and 
would appear to be followed by cell death. This observation correlates with the 
assay of the cleaved PARP protein using Western Blotting (see table 5.4). 
Cleaved PARP, a marker for apoptosis was not observed until 72 hours in 
those cells treated at the higher dose-rates.  
Taken together, these two sets of results lend support to the idea that below 
the proposed threshold dose-rate, cells undergo an early response to 
irradiation, whilst above this threshold there is a later delayed response to 
irradiation.  
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Figure 5.14 Change in relative cell viability during irradiation of PC-3 with Y-90 EDTA 
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 Initial Dose-Rate (Gy/hr) 
 0.5 0.3 0.2 0.1 0.05 0 
T=5 hrs 
 
 
T=72 hrs 
Table 5.4 Cleaved PARP Protein Levels in Irradiated PC-3 Cells 
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5.6 Discussion 
In chapter 5.3, an apparent inverse dose-rate response to beta irradiation in 
the prostate adenocarcinoma cell line, PC-3, was described. This response is a 
contradiction of the version of the Linear Quadratic Model developed for low 
dose-rate irradiation by Dale.  
The inverse dose-rate effect has previously been reported in the literature, 
particularly for prostate carcinoma cells. Deweese et al compared clonogenic 
survival at 0.25Gy/hr and 60Gy/hr in several malignant prostate cell lines 
including PC-3 [120]. In contrast to the results presented in this thesis, they 
found the low dose-rate irradiation to be more effective in terms of cell kill. The 
response of a range of cells, previously shown to exhibit hypersensitivity to low 
doses, in response to low dose-rate irradiation has also been investigated by 
Mitchell et al [62]. The cell lines included PC-3 as well as a glioblastoma cell 
line (T98G) and glioma cell line (A7). The experimental arrangements were 
different to those described in this thesis, in that cells were irradiated at 
continuous dose-rates within a water tank for much longer periods of time (up 
to 24 days). Media was changed only every seven days. Nonetheless, the 
authors observed an inverse dose-rate effect in all these cell lines, including 
PC-3.  However, for all 3 cell lines, the surviving fraction of cells was always 
greater than that when exposed to a single fraction of high dose-rate irradiation. 
An important question to ask, is to what extent could in-vitro demonstrations of 
hypersensitivity, or the inverse dose-rate effect, extrapolate into clinical benefit?  
Although hypersensitivity is a low dose phenomenon, it is relevant to note that 
EBRT is delivered by fractionating the total dose into daily doses of 2Gy. 
Furthermore, TRT can be considered to be a dose delivery based upon 
infinitely small dose fractions immediately followed by the next. 
In external beam radiotherapy, predictions based upon modelling smaller and 
more frequent fractions of radiation have suggested that hypersensitivity may 
lead to better outcomes [121, 122]. However, experimental investigations of 
ultrafractionation, whereby radiation is delivered in fractions of ~0.5Gy, 2-3 
times per day rather than conventional daily fractions of 2Gy, have delivered 
mixed results. Preclinical investigations, comparing ultrafractionation vs. 
conventional fractionation, of T98G and A7 xenografts in nude mice concluded 
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that conventional fractionation was more effective, despite the evidence of 
hypersensitivity observed in-vitro [123, 124]. However, a clinical trial of 
ultrafractionation in 31 patients with unresectable glioblastomas claimed an 
advantage over conventional radiotherapy, in terms of overall and progression 
free survival [125]. Further clinical evidence in favour of ultrafractionation was 
described by Harney et al. This group recruited patients with metastatic skin 
nodules and compared responses in randomly matched pairs of nodules, 
treated with either ultrafractionation or conventional fractionation [126].  
Typical dose-rates for TRT have been reported as being in the range of 0.08 – 
0.33Gy/hr [127]. i.e. the same order of magnitude as the dose-rates used for 
these in-vitro experiments. Despite this, there is rather less evidence regarding 
the clinical advantage of using lower dose-rates in the context of TRT. This is 
partly due to the limited cross over between tumour types demonstrating an 
inverse dose-rate effect (primarily glioma, glioblastoma and prostate cell lines) 
and the established radiopharmaceuticals available. However, in the case of 
prostate cancer, it is possible to compare brachytherapy treatments using 125I 
seeds implanted in the prostate bed, with external beam radiotherapy. If the 
dosimetry of each modality is compared, then the BED for brachytherapy with 
125I is usually ~145Gy [128]. In the case of EBRT it is either the same or higher 
[102, 127], yet comparisons of the two treatment modalities consistently show 
improvement in biochemical tumour control using low dose-rate brachytherapy 
[130-132]. TRT is routinely applied as a palliative therapy for prostate cancer 
patients with bone metastases. A number of radiopharmaceuticals are 
available with half-lives ranging from 1.9 days to 50.5 days. However to date, 
comparisons of these options have consistently failed to demonstrate any 
difference in effectiveness between these radiopharmaceuticals [133, 134].  
A version of the Linear Quadratic model which can account for inverse dose-
rate effects was described in chapter 5.4. In this adaptation of Dale’s model of 
response to an exponentially decaying dose-rate, the repair parameter , is a 
function of either the initial dose-rate, or the average dose-rate over the 
treatment time. This model is based upon a number of assumptions. Primarily, 
a change in the efficiency with which DNA is repaired is assumed to be the 
underlying mechanism behind the inverse dose-rate effect. Also, the increased 
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radiosensitivity is based upon the premise of a threshold dose-rate below 
which, repair processes are deficient. 
It is assumed by most authors that the inverse dose-rate effect is a 
consequence of the hyper-radiosensitivity effect and that they share the same 
underlying biological mechanism [56, 60, 115, 135]. Explanations of hyper-
radiosensitivity at low absorbed doses are centred on the inactivation of the 
G2-M cell cycle checkpoint at low absorbed doses of radiation. 
Two distinct checkpoints at G2-M have been described [136]. The first relates 
to G1 and S phase irradiated cells, which will accumulate in G2 as a result of 
the checkpoint. A second checkpoint relevant to cells irradiated in G2 is 
thought to be behind hyper-radiosensitivity. This checkpoint has been 
described as being activated by ATM at a threshold absorbed dose of ~0.4Gy 
which matches the threshold absorbed doses observed in hypersensitive cell 
lines [135-137].  Indeed, in a study of synchronised V79 Chinese Hamster cells, 
hypersensitivity was found to be confined to G2 phase cells only [138]. Cells 
lacking functional ATM have also been shown to have an increased sensitivity 
to low dose-rate irradiation [140, 141]. 
Although experimental evaluation of ATM-p(ser1981) levels could not be 
achieved, Checkpoint2 kinase is one of the downstream events initiated by 
ATM activation in response to DNA damage that ultimately leads to cell cycle 
arrest between G2 and M phase. Phosphorylation of Chk2 has been previously 
demonstrated in PC-3 cells [140] and linked to the G2 specific cell cycle arrest 
described above [143]. Thus if Chk2-p is considered a surrogate marker for 
ATM phosphorylation, the results presented in this thesis suggest that the 
ATM-Chk2 pathway is not activated in irradiated PC-3 cells until a threshold of 
~0.6Gy is reached. Once activated, the levels of Chk2-p are absorbed dose 
independent. Both of these observations are in keeping with the descriptions of 
hypersensitivity. However, there is no threshold dose-rate below which this 
pathway is not followed, suggesting that inverse dose-rate effects may not 
necessarily be explained by a failure to prevent damaged cells passing into 
mitosis. This is in contrast to the findings of Collis et al [108], who as well as 
observing a higher clonogenic cell kill in PC-3 and DU-145 (another prostate 
cancer cell line) treated to 2Gy at 0.1Gy/hr compared to 45Gy/hr, also 
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observed a lack of ATM-p(ser1981) in DU145 cells treated at the lower dose-
rate.  
In fact, a dose-rate dependence of Chk2-p is seen in HL60, whereby lower 
levels are observed at low dose-rates. As shown in chapter 4, this cell line 
does not appear to have an inverse dose-rate effect. However the changes in 
Chk2-p over time do correlate with investigations by Vavrova et al into this cell 
line [106]. They showed continued accumulation in G2 at 0.2Gy/hr whilst cells 
irradiated at 0.1Gy/hr moved through G2 or underwent apoptosis by 48 hours. 
Essentially this would suggest that a dose-rate dependent step function in the 
activation of G2/M cell cycle arrest is not a signature of the inverse dose-rate 
phenomenon. 
There are further reasons why the assumed biological mechanism given to 
explain hypersensitivity to acute radiation may not be the underlying cause of 
the inverse dose-rate effect. In the extension of the LQ model,  is changed as 
a function of dose-rate. This parameter describes the repair rate of single 
strand breaks in DNA. Although ATM is an effector of DNA repair, it has been 
associated primarily with the repair of double strand breaks [144-146].  
An alternative explanation may lie with Poly(ADP-ribose) polymerase (PARP), 
a protein associated with single strand repair [147, 148]. The relevance of 
PARP to hypersensitivity is less well understood, but PARP inhibition has been 
shown to sensitise cells to radiation at low absorbed doses [149]. In the results 
presented cleaved PARP, a surrogate marker for apoptosis, was not detected 
until 72 hours after treatment had started, and not detected at all at dose-rates 
below 0.3Gy/hr. However, it is not possible to draw definitive conclusions 
regarding PARP’s role as an effector of DNA repair as a function of dose-rate. 
A similar absence of apoptotic activity in hypersensitive cells (glioma U118MG 
and colon HT29) exposed to low dose-rate irradiation was observed by 
Carlsson et al [150].  
In conclusion, the existence of an inverse dose-rate effect has been confirmed 
in the PC-3 cell line. Moreover, the Linear Quadratic model has been extended 
to describe the situation whereby the rate of repair of single strand breaks is a 
sigmoid function of dose-rate. Such a model correctly predicts the existence of 
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an inverse dose-rate effect. Nevertheless, the underlying mechanism of such 
an effect remains unclear. 
For further validation of this model, it would be important to repeat the 
experiments described in this chapter with further cell lines also known to be 
associated with hypersensitivity. The clinical relevance of the inverse dose-rate 
phenomena to TRT should also be investigated using preclinical animal 
models alongside appropriate radiopharmaceuticals.  
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6 Bystander Effects 
 
6.1 Introduction  
The concept of the bystander effect was introduced in chapter 1.3.7, whereby 
cell death can be elicited in non-irradiated cells, due to interactions with 
neighbouring irradiated cells. Demonstrations of the effect fall into two 
categories, either by using media transfer experiments or by using alpha 
particle microbeams to target individual cells. The extent to which these effects 
are clinically important in either EBRT or TRT remains unclear. In the case of 
EBRT, the absorbed dose distribution at the microscopic level is relatively 
homogenous. i.e. any irradiated cell receives the same absorbed dose as its 
neighbours. Thus, the effect of any potential bystander effect is included in the 
measured overall response to irradiation. In the case of TRT treatments, there 
is a greater tendency for absorbed dose distributions to be heterogeneous at 
the microscopic scale, especially if low energy beta emitters or even alpha 
emitters are used. Therefore it is reasonable to postulate that a better 
understanding of the spatial propagation of bystander effects may be 
necessary to fully interpret dose-response relationships. Furthermore, the 
investigations by Boyd et al into bystander effects elicited by cells targeted with 
radionuclide labelled MIBG demonstrating a greater toxicity of media from 
131MIBG treated cells (up to 70% cell kill) compared to media from EBRT 
treated cells (maximum 40% cell kill) suggest an important difference in the 
bystander response at different dose-rates. Thus, the bystander effect may be 
of particular importance in understanding the response of cancer cells to TRT 
and may not be well modelled by current versions of the Linear Quadratic.  
The aim of this chapter was to identify a cell line exhibiting a bystander effect in 
response to EBRT, which could also be specifically targeted with an 
appropriate radiopharmaceutical. The cell line would be used as the basis for a 
series of preliminary media transfer experiments to investigate the bystander 
effect in TRT. In order to investigate the spatial propagation of the bystander 
effect, it was also desirable that the cell line could be manipulated to form 
spheroid aggregations of cells.   
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6.1.1 Cell Selection 
Two breast carcinoma cell lines, BT-474  and T47D,  were identified as 
potential candidates on the basis that they had previously been shown to 
aggregate into spheroids if grown in appropriate conditions [151].  
In order to successfully radiolabel these cells, their respective receptor 
expression was considered. From the literature BT-474 was thought to express 
the HER2 receptor [67] but not the HER1 (EGFR) receptor [152]. Conversely it 
would appear that T47D cells express EGFR receptors but not HER2 [153]. 
The advantage of seeking to target HER2 and EGFR, was that commercial 
immunotherapy treatments that target these receptors are available, namely 
Herceptin and Cetuximab. However, only Herceptin could be sourced for use in 
these experiments. Therefore, it was decided to proceed with investigation of 
the BT-474 cell line only.  
Before carrying out a series of clonogenic assays on irradiated BT-474 cells, a 
test experiment was carried out using the ATP viability assay. Media was 
transferred from flasks of BT-474 cells irradiated using EBRT to 10Gy, to 
unirradiated flasks of cells at 4 hours post irradiation and 48 hours post 
irradiation.  
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Figure 6.1 Initial testing of BT-474 for bystander effect. ATP viability assay of cells treated with 
media transferred from BT-474 treated with 10Gy EBRT. 
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The results of this experiment (see figure 6.1) suggested that a bystander 
effect can be observed. No difference was observed between the effects of 
media transferred 4 hours post irradiation and that transferred 48 hours post 
irradiation.  This would suggest that the effectors of cell death are released by 
cell cultures relatively quickly and that they persist for at least 48 hours. 
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6.2 Response of BT-474 to EBRT 
Adherent BT-474 cells were grown as described in chapter 2.1. For delivery of 
acute irradiation, the 137Cs Irradiator was used (chapter 2.2). Cell survival was 
assessed using a clonogenic assay using Crystal Violet staining (chapter 2.3.) 
A total of 18 25cm2 flasks of BT-474 cells were prepared. Of these, 12 
(including two negative controls) were irradiated with absorbed doses of up to 
10Gy. The remaining 6 were designated as recipient cultures for bystander 
experiments.  
 
6.2.1 Direct Irradiation 
6 of the 12 irradiated flasks were incubated for 48 hours before being seeded 
for clonogenic assay.  
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Figure 6.2 Survival of BT-474 cells in response to single fraction EBRT. 
 
The cell survival curve for BT-474 in response to acute single fraction 
irradiation is shown in figure 6.2. As previously, the data was modelled to a 
linear quadratic function using a least squares fit. The model parameters were 
 = 0.221Gy-1 ± 0.01 and  = 0.018Gy-2 ±0.001. Thus / = 12Gy. Of note are 
the relatively large error bars, compared to the previous results obtained with 
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the crystal violet clonogenic assay presented in chapter 5. The error bars 
reflect the variation in the number of colonies formed within triplicate sets of 
measurements. The data shown is the result of two independent experiments. 
The alpha/beta ratio is larger than that observed when HL60, MOLT4 and 
particularly PC-3 cells were irradiated. However, this magnitude of alpha/beta 
ratio is more typical of most solid tumour types.  
 
6.2.2 Bystander Response  
At 24 hours post irradiation, media was aspirated from the 6 flasks designated 
as recipient cultures. This was replaced with media from the 6 EBRT irradiated 
flasks (including a negative control) not destined to be seeded for clonogenic 
assessment. After further incubation for 24 hours, these recipient cell cultures 
were seeded for assessment of clonogenic survival at the same time as the 
remaining set of 6 irradiated flasks. 
The effect of the transferred media is shown in figure 6.3a. A Mann-Whitney 
test revealed a significant difference between the number of control colonies 
grown and the number of colonies resulting from the recipient cells (p<0.05). 
The maximum cell kill (~50%) was caused by media transferred from the cells 
irradiated with the lowest absorbed dose, 0.5Gy. Beyond this radiation 
absorbed dose, the cell kill elicited by the transfer of media remained 
independent of the absorbed dose delivered to the irradiated donor cells (40-
45%). One of the most striking aspects of the observed results is the fact that 
for low absorbed doses, the bystander effect appears to be more toxic that 
direct irradiation. This might suggest that a by-product of irradiation may 
provide a protective effect against the toxins that are responsible for the 
bystander effect in media transfer experiments. 
In order to confirm these observations, the experiment was repeated on a 
separate occasion. Although, the same response to direct irradiation (i.e. the 
standard cell survival curve) was observed (see figure 6.2) a less striking 
bystander response was observed (see figure 6.3b). In this case, the difference 
between the number of control colonies and the number of recipient colonies 
was not significant (p=0.1). However, in the case of this 2nd experiment, the 
initial number of cells per flask was less than in the first case by a factor of 2 
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(as determined by the relative number of colonies grown in the negative control 
plates.) It could therefore be argued that the higher number of irradiated cells 
in the first experiment led to a higher concentration of toxins in the transferred 
media, which was subsequently more effective against the recipient cell 
cultures.  
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Figure 6.3 The effect of media from irradiated BT-474 cells on unirradiated BT-474 cells. A) First 
independent experiment. B) 2nd independent experiment. The LQ response to single fraction 
EBRT is shown for comparison. 
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Figure 6.4 Summary of Bystander Effect from EBRT irradiated BT-474 cells 
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6.3 Dose Response of BT-474 Cells Exposed to LDR 
6.3.1 Treatment with 90Y-EDTA 
Prior to investigating any bystander effect caused by cells exposed to low 
dose-rate beta emissions, a study to establish the response to direct irradiation 
at low dose-rates was carried out.  
In chapter 6.2, the response to EBRT was established. The higher alpha/beta 
ratio of 12 means that in principle, the response is more linear than for other 
tissues over the range of doses applied and hence the effects of fractionation 
may be less significant than for tissues or cells with a lower alpha/beta ratio. 
Therefore, BT-474 cells were treated over either 24 or 96 hours, since it was 
anticipated that if the LQ model was predictive of the dose-response 
relationship, then changes in dose-rate would have less effect than in other cell 
lines such as the PC-3. 
As previously, cells were irradiated with 90Y-EDTA in a 2.5ml volume of cell 
culture. At either 24 hours or 96 hours, the radioactive media was aspirated 
and cells were diluted into fresh media for assessment of clonogenic survival.  
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Figure 6.5 Response of BT-474 to 
90
Y-EDTA 
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The results of these experiments are shown in figure 6.5. Over the range of 
0.5Gy – 10Gy, the observed survival in response to 90Y-EDTA is generally 
closely matched to that seen in response to EBRT. It is possible that at lower 
absorbed doses up to 5Gy, the efficacy of the treatment is greater than with 
EBRT. However, this may be due to experimental uncertainties associated with 
the clonogenic assay as mentioned in the previous section. At 20Gy, no 
surviving colonies were observed for cells irradiated over 24 hours, whilst a 
single colony (out of 3 triplicate wells) was measured in the case of cells 
irradiated over 96 hours. The data points therefore represent the maximum 
possible survival at 20Gy, but it not possible to define precise clonogenic 
survival at 20Gy. In terms of dose-rate, a significant difference between 
treatments over 24 hours vs 96 hours was not observed (p=0.37). 
As previously, the precise predictions of Dale’s version of the LQ model 
applied to an exponentially decaying dose-rate at higher absorbed doses, are 
dependent on the value assigned to the repair parameter . In figure 6.6, two 
alternative possibilities are presented. In one case,  = 0.035 equivalent to a 
repair time of 20 hours. This provides a better fit to the data but makes use of a 
theoretically unsound repair time which is much longer than that normally 
assumed of 1-2 hours.  If a repair time of 2 hours (=0.35) is used instead, 
then a possible interpretation of the results is that cells are more sensitive to 
TRT than predicted by LQ parameters derived from response to EBRT (see 
figure 6.6b). On the other hand, it can also be seen that the reproducibility of 
the clonogenic response is poor and that therefore this interpretation should be 
treated with caution. 
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Figure 6.6 Linear Quadratic model applied to 
90
Y-EDTA treatment of Bt-474 cells. Results are 
shown for an assumed repair time of A) 20 hours and B) 2 hours. 
B) 
A) 
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6.3.2 Treatment with 90Y-DOTA Herceptin 
In order to carry out media transfer experiments to investigate potential 
bystander effects, an alternative to 90Y-EDTA was required, since a 
requirement of such studies is that the media transferred is itself free of 
radioactivity. 
Therefore the procedure described in chapter 2.2.4 was developed to label 90Y 
to DOTA conjugated Herceptin. The hope was that 90Y-DOTA-Herceptin would 
specifically bind to the HER2 receptor expressed on BT-474, thus providing 
localised low dose-rate irradiation at the same time as removing at least some 
of the 90Y-DOTA-Herceptin from the cell culture media. 
As well as a bystander response, the result of direct exposure to this 
radiopharmaceutical was also measured, since it was thought that the 
interaction of the Herceptin antibody with its receptor may have the potential to 
change the observed response of the cells to increasing absorbed doses of 
radiation. 
The immunotherapeutic effect of the radio-labelled antibody was controlled by 
adding an amount of unlabelled DOTA-Herceptin to the 90Y-DOTA-Herceptin, 
such that the total amount of antibody was consistent across all wells, 
regardless of the amount of radioactivity added. A positive control treatment 
consisting of cold antibody only was included in the experimental set up (as 
well as a negative control). Clonogenic survival results were calculated relative 
to the positive control group in order to ascertain the effects of the radiation 
alone. The activity added ranged from 0.3MBq to 6MBq.  
In practice, not all of the added 90Y-DOTA-Herceptin was taken up by the BT-
474 cells. In order to ascertain the concentration of radioactivity remaining in 
the cell culture media, 150l samples were taken (in triplicate) and counted on 
the gamma counter against an 90Y standard derived from the original stock of 
90YCl. The amount of radioactivity bound to the cells was measured by 
sampling the cell culture during the process of seeding cells for the clonogenic 
survival assay. After cells in the 6 well plates were trypsinised and 
resuspended in 5ml cell culture media, 150l samples were taken and counted 
against the 90Y standard.  
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Hence, calculations of absorbed dose were made by summing the relative 
contributions of the activity bound to the monolayer as well as that from activity 
uniformly distributed in the media (see chapter 3.3.2 for details). 
The results shown in figure 6.7 reflect two independent experiments. In the 
original experiment (marked in red), after adding 90Y-DOTA-Herceptin to BT-
474 and placing them on rollers for two hours, the cells were spun down and 
supernatant (together with the unbound 90Y-DOTA-Herceptin) removed prior to 
adding fresh media and resuspending and incubating the cells for 72 hours. 
Samples of the removed supernatant were assayed for radioactivity against a 
standard in order to calculate the amount of unbound radiopharmaceutical. In 
practice this unbound activity represented up to 98% of the total activity added 
to each sample. Hence, the range of absorbed doses covered is relatively 
small compared to previous experiments. 
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Figure 6.7 Clonogenic cell survival in response to 
90
Y-DOTA-Herceptin vs +ve Herceptin control 
 
Therefore in the second experiment unbound activity was not removed in order 
to extend the range of absorbed doses applied. Hence, the absorbed dose to 
cells resulted from both radioactivity bound to the cells as well as unbound 
radioactivity in the cell culture media. The presence of unbound radioactivity in 
the media implies a saturation of the HER2 receptors on the cells. However, 
the total uptake of activity into cells was ten times greater on the second 
occasion in comparison with the first experiment. As described in chapter 2.2.4, 
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the labelling procedure was optimised to maximise the specific activity. 
Nonetheless, although the labelling procedure used was consistent on each 
occasion, there was a clear difference in the resulting uptake of 90Y-DOTA-
Herceptin by BT-474 cells.  
Relative to the negative control cells the positive control cells formed 75% 
fewer colonies as a result of the Herceptin alone. Since the total amount of 
antibody was kept consistent over all doses, figure 6.7 shows the effect of the 
radiation alone. Thus it could be seen that the response appeared to broadly 
follow that seen in response to 90Y-EDTA, although the effect at higher 
absorbed doses was not so toxic. Again, cell survival observed at low 
absorbed doses appeared to be lower than had previously been observed in 
response to a single fraction dose of EBRT. 
 
6.3.3 Bystander Response (from 90Y-DOTA-Herceptin) 
The original reason for using a radio-labelled antibody to investigate bystander 
responses was that specific uptake of the radiopharmaceutical could result in 
cell culture media  that was free of radioactivity and could be transferred to 
recipient cell cultures. However, as described above complete uptake of the 
90Y-DOTA-Herceptin could not be achieved. 
Therefore an affinity chromatography technique using columns of Protein A 
beads was used to filter the media for transfer and specifically remove the 
radio-labelled Herceptin antibody (see chapter 2.4.4).  
90Y-DOTA-Herceptin was added to aliquots of BT-474 cells (designated as 
donor cells) at activities ranging from up to 6MBq as described in chapter 6.3.2. 
At the same time, a set of recipient cell cultures were set up.  After 24 hours 
incubation, the media from the donor cultures was passed through a Protein A 
column until no further activity could be extracted. Media from the recipient cell 
cultures was aspirated and replaced with the filtered “bystander” media. The 
recipient cells were subsequently incubated for a further 48 hours before being 
prepared for clonogenic assay. Media from these cells was sampled and 
assayed for radioactivity concentration as previously described in order to 
calculate the direct dose to these cells from the transferred radioactivity. 
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Samples of the recipient cells were also assayed for radioactivity resulting from 
bound 90Y-DOTA-Herceptin. 
In response to the transferred media from irradiated BT-474 cells, a toxic 
bystander effect was not observed (see figure 6.8a). The hypothesis that the 
toxic effects of the transferred media, would closely match the toxicity of direct 
irradiation with 90Y-DOTA-Herceptin could not be confirmed. Although there 
was some loss of clonogenic survival, it correlated with the LQ response which 
would be anticipated from direct irradiation as a result of 90Y radioactivity which 
could not be extracted from the transferred media (r2 = 0.33).  
 
 
6.3.4 Bystander Response (from 90Y-DTPA-YAML568) 
A bystander response could not be elicited by transferring the media from 90Y-
DOTA-Herceptin irradiated BT-474 cells to untreated BT-474 cells. In order to 
rule out an inhibitory effect of the Herceptin antibody, it was decided to repeat 
the experiment using a non-specific antibody, YAML568, which could be 
labelled with 90Y and used to irradiate BT-474 in a similar fashion to 90Y-EDTA, 
but subsequently filtered from the media using the affinity chromatography 
techniques already developed for working with 90Y-DOTA-Herceptin.  
Aliquots of BT-474 cells were prepared in 6 well plates (2.5ml media per plate) 
as for previous experiments. Donor and recipient aliquots were taken from the 
same parent flask. The donor aliquots were treated with activities up to 13MBq 
(~25Gy). After 24 hours the media was removed from the donor cultures and 
passed through Protein L columns. The filtered media was used to replace the 
media from the recipient cell cultures. After a further 48 hours, the recipient cell 
cultures were set up for clonogenic assay. As before the activity concentration 
in the transferred media was measured and used to calculate the direct dose to 
the recipient cells.  
As with irradiation with 90Y-DOTA-Herpcetin, media transferred from 90Y-
DTPA-YAML568 irradiated BT-474 cells, did not result in an observable 
bystander effect (see figure 6.9).   
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Figure 6.8 Bystander Effect of Media transferred from 
90
Y-DOTA_Herceptin treated BT-474 cells 
and passed through Protein A Column. Clonogenic Survival plotted as a function of A) Dose to the 
Donor Cell Cultures and B) Dose to the Recipient Cell Cultures as a result of residual 
radioactivity in transferred media. 
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Figure 6.9 Bystander Effect of Media transferred from 
90
Y-DTPA-YAML568 treated BT-474 cells 
and passed through Protein L Column. Clonogenic Survival plotted as a function of A) Dose to the 
Donor Cell Cultures and B) Dose to the Recipient Cell Cultures as a result of residual 
radioactivity in transferred media. 
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6.4 Discussion  
The breast adenocarcinoma cell line BT-474 was characterised for 
radiosensitivity to single fraction irradiation using the LQ model. An / ratio of 
12Gy was measured. This measured response to gamma irradiation is of the 
same magnitude as found by other investigations using this cell line [154]. 
Furthermore, the analysis of clinical treatments of breast cancer by Guerrero et 
al has confirmed the relatively high / ratio in-vivo [155]. 
This higher ratio is more typical of solid tumours. From the LQ model it follows 
that over the ranges of absorbed doses considered, the BT-474 cells are less 
affected by fractionation or changes in dose-rate, since the D term will 
dominate to a greater extent than for cell lines with a lower /such as HL60 
or MOLT-4This is reflected in the clonogenic survival of BT-474 in response to 
90Y-EDTA. Up to absorbed doses of 10Gy, there is no appreciable difference 
between the survival of cells treated over 24 hours or 96 hours. Neither 
treatment is significantly less effective than the single fraction EBRT.  
In order to achieve a best fit of the LQ survival to the experimental data a 
repair time of 20 hours was suggested. Such a figure is substantially more than 
the values typically assumed and indeed more than the figure of 1 hour 
calculated by Guerrero et al [155]. However, when a repair time of 2 hours was 
assumed then the measured cell survival was generally 50% less than that 
predicted. It is debatable whether this was a result of experimental 
uncertainties in the determination of the alpha and beta parameters, or whether 
these results imply an additional cell kill as a result of the bystander effect. 
The bystander effect can be defined as the response of a non-irradiated cell 
brought about by the targeting of its neighbour with irradiation (or indeed any 
other type of stress). The clinical relevance of this phenomenon is debatable – 
in the case of EBRT the radiation absorbed dose to neighbouring cells is likely 
to be effectively identical. Even for dose distributions resulting from Beta 
emitting radiopharmaceuticals such as 90Y or 131I, this is likely to be the case. It 
may only be particularly relevant for Alpha or Auger emitting 
radiopharmaceuticals. 
There would appear to be two distinct mechanisms for bystander effects [156]. 
In the first case direct cell to cell communication may occur between irradiated 
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cells and their neighbours via gap junctional intercellular communication (GJIC). 
Separate studies have shown the range of these effects may be between 
40mm to 1mm from the site of the radiation energy deposition [157, 158] . 
However GJIC is generally a property of normal cells, which is not present in 
cancer cells [159]. (As a consequence, therapies aimed at restoring GJIC have 
been proposed as a means of sensitising cancer cells to existing treatments 
[160, 161].) The second mechanism for the bystander effect is the release by 
irradiated cells of various cytokines, such as interleukin-6, interleukin-9 and 
tumour necrosis factor  [156].    
It is this mechanism which underlies the toxicity of transferred media from 
irradiated cells to non-irradiated cells. Toxicity from transferred media was 
observed when BT-474 cells were exposed to media from irradiated BT-474 
donor cells, using both an ATP assay as well as the clonogenic assay. As in 
previous studies, the effect appeared most significant at low absorbed doses, 
but beyond 1Gy was dose independent [162, 163]. A potentially significant 
difference between these previous studies and those results presented is the 
apparent increased toxicity of the bystander effect in comparison with direct 
irradiation at absorbed doses <2Gy. Previous analyses have made the 
assumption that the direct effect of ionising radiation and the bystander effect 
were additive. These observations of BT-474 cells would indicate that 
irradiation of cells may trigger an inhibitory response against any cytokine 
factors released into media. i.e. the effects are not additive.  
The association of bystander responses with low absorbed dose in particular, 
has prompted the hypothesis that bystander effects could be of further 
significance to cells treated with higher absorbed doses delivered at lower 
dose-rates. This was one of the main findings of the investigations of Boyd et 
al [65] in which alpha, beta or Auger emitting radionuclides were used to 
radiolabel MIBG and used to treat cells transfected with the Noradrenaline 
Transporter (NAT) gene. Clonogenic survival was measured in response to 
direct irradiation as well as to transferred media. The effect of the media from 
cells treated with 131I-MIBG (a beta emitter) was found to closely follow that of 
direct irradiation and no plateau was observed. This finding is in contrast with 
the lack of any observable bystander response to the media from BT-474 cells 
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treated with 90Y-DOTA Herceptin or 90Y-DTPA-YAML568. It is possible to 
hypothesise that, due the finite amount of radioactivity that could not be 
removed from the transferred media, this discrepancy may be due to the 
protective effect of low absorbed doses of radiation implied by the results 
observed in response to EBRT. It is also possible that the Protein-L affinity 
columns removed any toxic bystander effect mediators from the culture media. 
Other investigations of bystander effect arising from cells irradiated using 
radionuclides have also yielded negative results. Whilst Kishikawa et al 
observed a bystander response (both in-vivo and in-vitro) from LS147T colon 
carcinoma cells targeted with the thymidine analog 125I-5-iodo-2’-deoxyuridine 
(125IdUrd), the use of 123IdUrd was found to have a stimulatory effect [164]. 
Differences in Linear Energy Transfer (LET) have been proposed as a potential 
explanation for variations in the observed bystander effect in response to 
irradiation with different radionuclides [165]. For example, Anzenburg et al 
investigated bystander responses in both DU145 prostate carcinoma cells and 
AG01522 skin fibroblasts, when DU145 cells were irradiated with either X-rays 
or alpha particles [166]. A (clonogenic) bystander response was observed in 
the AG01522 cells when the DU145 were exposed to low LET X-ray radiation 
but not in response to high LET alpha radiation. However, a difference in LET 
is less likely to explain the different bystander response of BT-474 to EBRT vs 
90Y irradiation. The LET of electrons arising from 137Cs and 90Y irradiation are 
~1keV/m and 0.26keV/m respectively, compared to 60-100keV/m in the 
case of alpha emitters [47, 167, 168]. Furthermore, Anzenburg et al found that 
neither irradiation with X-rays or alpha particles elicited a bystander response 
in the DU145 cells themselves. i.e. as well as consideration of the type of 
radiation, a better understanding of the biological response to factors released 
by irradiated cells is required to predict the significance of these effects on 
cancer (and normal) cells.   
The dosimetry results for a spheroid of cells with surface bound 
radiopharmaceutical presented in chapter 3.4 gave rise to an alternative 
experimental approach to investigating bystander effects. It was noted that 
different sized spheroids, which bound 90Y radioactivity in proportion to their 
surface area, would have the same dose volume histogram and hence the 
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same theoretical fraction of surviving cells. It could be hypothesised that any 
differences in cell survival could be due to the finite propagation of a bystander 
effect through different sized spheroids. Such an approach would include GJIC 
effects as well as cytokine release, and could provide an experimental basis for 
evaluating any future mathematical models of low LET bystander effects. (A 
number of models have already been developed for analysing high LET 
bystander effects [169, 170, 171].) Unfortunately, uptake of 90Y-DOTA-
Herceptin by BT-474 cell spheroids sufficient to cause clonogenic cell kill could 
not be achieved.  
Nonetheless, the treatment of BT-474 monolayers with 90Y-DOTA-Herceptin 
yielded interesting results. Herceptin is the commercial name of Trastuzumab, 
a monoclonal antibody with affinity for the Her2 receptor expressed by 20-25% 
of breast cancer tumours. It is used for treatment of metastatic breast cancer 
and may also be used as part of first line treatment of early breast cancer [172]. 
Herceptin promotes cell cycle arrest (particularly during G1) and apoptosis by 
reducing the signalling of MAPK and PK13 pathways [173]. Radio-labelled 
Herceptin has been proposed by several groups as a novel therapeutic 
radiopharmaceutical [174-178]. 
When BT-474 cells were exposed to 90Y-DOTA-Herceptin the clonogenic 
response to irradiation relative to a positive control was the same as that 
observed in response to 90Y-EDTA. i.e. despite the possibility of competing 
molecular signalling pathways in response to both irradiation and Herceptin, 
the LQ model was still able to predict the additional cell kill effect of increasing 
the absorbed radiation dose. 
In conclusion, a cell line demonstrating a bystander effect was identified. It’s 
response to low dose-rate irradiation was observed to conform to that 
predicted by the LQ model. However, there are some limitations to the 
experimental design that must be considered. The media transfer experiments 
involving 90Y failed to elicit a bystander effect in BT-474. In order to rule any 
potential filtration of toxins by the Protein-L affinity columns, the method could 
be validated using the cell lines previously demonstrated by Boyd et al to 
exhibit a bystander response to low dose-rate irradiation. 
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7 Concluding Remarks 
 
The version of the Linear Quadratic model developed by Dale [104] has been 
shown to accurately predict the response of a range of cell lines to low dose-
rate irradiation using radionuclides. This confirmation of the validity of the 
model is particularly important, since it is increasingly being applied to 
evaluations of dose-response in the clinical setting [179],[38]. Such 
approaches should therefore lead towards an improved correlation between 
dosimetry and treatment outcome, both with respect to tumour control as well 
to unwanted side effects. 
An exception to this case has been the PC-3 prostate carcinoma cell line, 
which displayed an inverse dose-rate effect counterintuitive to the response 
predicted by the LQ model. This increased sensitivity to low dose-rate 
irradiation may be explained by modelling the repair parameter  as a sigmoid 
function of dose-rate rather than as an absolute constant. In cell lines 
displaying a conventional dose-rate response, the LQ model was predictive of 
response.  
In addressing the question of whether the LQ model is able to address 
clonogenic survival, a number of secondary issues have also been investigated. 
A number of reasons why the radiobiology of TRT may differ to that of EBRT 
have been previously raised in the literature, in particular the role of apoptosis 
as a route to cell death in response to low dose-rate treatment; the question of 
whether low dose hypersensitivity will translate into low dose rate 
hypersensitivity; and whether bystander effects play a more significant role in 
response to low dose-rate irradiation. 
Apoptosis is undoubtedly an important part of the response of cells to radiation, 
and it has been shown in this thesis and by others that treatment with low 
dose-rate irradiation can indeed elicit this response. However, it may not be the 
case that apoptosis is a mode of cell death that should be specifically 
associated with one method of radiation delivery over another.  
Low Dose Hypersensitivity is a phenomenon that may well be a marker of 
tumour types that will not follow the predictions of the LQ model as well as 
being more sensitive to TRT. However, whilst cells displaying LDH have been 
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shown to exhibit an inverse dose rate effect, the threshold activation of the 
G2/M cell cycle checkpoint which has been cited as being the underlying cause 
of LDH does not appear to be the defining basis for increased sensitivity to low 
dose rate hypersensitivity. Whatever, the underlying cause of the inverse dose-
rate effect, the limitations of the LQ model in in-vitro investigations of certain 
cell lines, should be considered when future work is extended to in-vivo models.  
It is harder to draw firm conclusions regarding the relative importance of the 
bystander effect. In the case of the BT-474 breast carcinoma investigated, 
preliminary investigations using media transfer experiments have suggested 
that irradiation may promote protection against the cytokine mediated toxicity 
of the bystander effect. If this were generally the case, then the significance of 
the bystander effect may be limited to higher LET particles such as Auger 
electrons or alpha particles, whose ranges do not extend beyond single cell 
diameters. Thus, the LQ model appeared to provide a reasonable prediction of 
dose-response whether to 90Y-EDTA or to 90Y-DOTA-Herceptin.  
However, the lack of bystander response observed in response to either 
treatment with 90Y-DOTA Herceptin or 90Y-DTPA-YAML568 was in stark 
contrast to the results of Boyd et al, who observed significant effects using 131I-
MIBG. Unfortunately the “dose” associated with the 131I-MIBG was expressed 
in units of radioactivity concentration rather than absorbed dose, making direct 
comparison of response to EBRT and TRT challenging. It therefore remains an 
open question as to whether a bystander effect elicited by TRT leads to a 
higher cell kill than predicted by the Linear Quadratic model.  
A continuing question is to what extent the three radiobiological phenomena 
discussed are interrelated. For example, several authors have investigated 
whether increased levels of apoptosis are associated with Low Dose 
Hypersensitivity. Marples et al found no correlation between LDH and 
apoptosis [61], as did Chanda et al [180].  In the case of this thesis, the results 
would also tend to suggest no correlation between apoptosis and the inverse 
dose-rate effect. The HL60 and MOLT-4 cell lines were both highly prone to 
apoptosis, but showed a conventional relationship between dose-rate and 
radiation sensitivity. The PC-3 cell line investigated in chapter 5 which 
displayed an inverse dose-rate effect did appear to be prone to apoptosis. 
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However, only those cells exposed to dose-rates above the threshold dose-
rate identified were positive for apoptotic cell death, indicating that if anything 
apoptosis and increased sensitivity to low dose-rate radiation were mutually 
exclusive.  
Inverse correlation has also been demonstrated between the bystander effect 
and Low Dose Hypersensitivity [181]. This would also appear to be the case 
with BT-474 – a cell line which demonstrated a clear bystander effect (at least 
in response to EBRT) but which also followed a conventional dose-rate 
response relationship.  
In drawing conclusions on dose-response relationships the reliability of 
accurate dosimetry has been of fundamental importance.  Monte Carlo 
simulations of electron interactions using PENELOPE were validated against 
reference data. The only previously published data on the dosimetry of 
radionuclides in cell cultures used convolution of analytical expressions of the 
dose point kernel to calculate doses. In comparison with the PENELOPE 
dosimetry, differences of up to 20% were noted. Such margins of error could 
have a significant effect on the interpretation of comparisons of response to 
EBRT and TRT.  
As with any investigation, there are certain limitations which need to be 
considered. Although, the calculation of absorbed dose, resulting from the 
application of radioactivity has been carried out to a high degree of accuracy, 
the calculation of absorbed dose relies upon the accuracy with which the 
amount of radioactivity itself has been measured. In general, a figure of ±5% is 
typical of the accuracy of radionuclide calibrators. 
Furthermore, the panel of cell lines used in this thesis was relatively narrow 
compared to the vast array of tumour cell lines available for study, and it 
should not necessarily be assumed that the results observed will translate to all 
cell lines. In particular, further work could be carried out with a second cell line 
displaying LDH to confirm the validity of the threshold repair extension of the 
LQ model.  
It should also be noted that this work concentrated exclusively on beta 
emissions, both from the point of view of dosimetry and biological effect. 
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Development of both alpha and auger emitting radiopharmaceuticals continue 
and this work does not address the validity of the LQ model in these situations. 
Neither can it be assumed that results observed in-vitro, will also be observed 
in-vivo. The main measure of response used in this thesis has been the 
percentage of clonogenic cells surviving. A natural extension of the in-vitro 
experiments carried out may be to investigate the ability of the LQ model to 
predict Tumour Control Probability (TCP) as well as Normal Tissue 
Complication Probability (NTCP) in pre-clinical animal models of particular 
cancer types. 
In addition, the methods and approaches taken in this thesis to explore general 
aspects of cancer cell response to TRT, should perhaps be incorporated into 
the development of new radiopharmaceuticals, in order to better select the 
approaches that may be most likely to result in a clinically effective treatment. 
In conclusion, the validation of the LQ response is particularly timely as 
radiobiological modelling based upon the LQ formalism is increasingly being 
advocated to augment the analysis of dose-response outcomes in clinical TRT 
[27, 182]. A minor drawback affecting the implementation of the LQ model in 
TRT may be the requirement for prior knowledge of the repair times associated 
with a particular tumour type. However, with tumour types of high / ratio in 
particular, a standard value of 1-2 hours should suffice. 
One of the remarkable aspects of the success of the LQ model is its basis on 
relatively simple concepts of the biological response to irradiation. In spite of 
the subsequent advances in the understanding of the many and various 
biochemical pathways that occur in response to ionising radiation, the LQ 
model has successfully underpinned the optimisation of radiation dose delivery 
in EBRT. There would appear to be no reason why the same approach should 
not be followed with respect to Targeted Radionuclide Therapy.  
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Appendix 1 
Derivation of S-Factor from ev per primary particle to mGy/MBq-s 
 
EeV is the energy per primary particle in units of eV 
 
EJ is the energy in SI units of Joules. 
 
D is the absorbed dose per primary particle in SI units of Gy. 
 
m is the mass of the geometric volume in SI units of kg 
 
m
E
D
EE
J
eVJ

 19106.1
 
 
The branching ratio of 90Y is 1. Therefore the dose per primary particle is 
equivalent to the dose per unit of cumulative activity (in Bq-s). 
 
 
63 1010)/(  DsMBqmGyfactorS  
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Appendix 2  
Solution to Incomplete Repair Model for finite treatment time T. 
 
Relative Effectiveness can be expressed as follows (in any situation) [103] 
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In the situation of a monoexponential dose-rate, 
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Relates to the probability of sub-lethal 
damage at time w prior to t that has not 
been repaired 
Relates to the probability of second 
incident of sub-lethal damage at time t  
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